<!DOCTYPE html><html lang="en-GB"><head><meta charSet="utf-8"/><meta http-equiv="x-ua-compatible" content="ie=edge"/><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/><style data-href="/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css" id="gatsby-global-css">.page-header{margin:0 0 3rem}.page-header__pre-heading{font-size:1.125rem;line-height:1.5rem;display:block;margin:0}.page-header__heading{font-size:2.75rem;line-height:3.5rem;margin:0 0 .5rem}.page-header__lead{font-size:1.25rem;line-height:1.75rem;margin:0 0 .5rem}.page-header__cta{font-size:1rem;line-height:1.5rem;display:block;margin:0}@media print{.page-header__cta{display:none!important}}.breadcrumbs{font-size:1rem;line-height:1.5rem;list-style:none;margin:.5em 0 2em;max-width:100%;padding:0}@media print{.breadcrumbs{display:none!important}}.breadcrumbs__crumb{display:inline-block}.breadcrumbs__crumb:before{content:">";font-size:80%;margin:0 .25em}.breadcrumbs__crumb:first-child:before{display:none}.breadcrumbs a{color:#222;text-decoration:underline}.breadcrumbs a:hover{text-decoration:none}.breadcrumbs a:focus{color:#005ea5}.breadcrumbs a:active{color:#222}.OldIEMessage-module--container--2Z9pT{max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);margin:auto auto 1rem}.OldIEMessage-module--alert--3CB3M{background:#ffdfa4;border:1px solid #966f2f;margin:1rem auto 0;max-width:73.125rem;padding:1rem}.OldIEMessage-module--alert--3CB3M a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.OldIEMessage-module--alert--3CB3M a:visited{color:#4c2c92}.OldIEMessage-module--alert--3CB3M a:hover{color:#2e8aca}.OldIEMessage-module--alert--3CB3M a:focus{outline:.25rem solid #0092a6;color:#005ea5}.OldIEMessage-module--alert--3CB3M a:active{color:#222}.OldIEMessage-module--alert--3CB3M h2{margin-top:0}.OldIEMessage-module--alert--3CB3M h2,.OldIEMessage-module--alert--3CB3M p{max-width:600px}.OldIEMessage-module--lastP---CQws{margin-bottom:0}.CoronaMessage-module--wrapper--zRiaV{background:#ffeb3b;padding:.5rem 0}.CoronaMessage-module--wrapper--zRiaV p{margin-top:0}.CoronaMessage-module--wrapper--zRiaV a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.CoronaMessage-module--wrapper--zRiaV a:visited{color:#4c2c92}.CoronaMessage-module--wrapper--zRiaV a:hover{color:#2e8aca}.CoronaMessage-module--wrapper--zRiaV a:focus{outline:.25rem solid #0092a6;color:#005ea5}.CoronaMessage-module--wrapper--zRiaV a:active{color:#222}@media print{.CoronaMessage-module--wrapper--zRiaV{display:none}}.CoronaMessage-module--container--36Biz{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.CoronaMessage-module--container--36Biz>:last-child{margin-bottom:0}.SubNav-module--wrapper--yAXWY{background:#fff;color:#000;display:block}.SubNav-module--list--1K9bK{margin:0;padding:0}.SubNav-module--list--1K9bK li{list-style:none;margin:0}.SubNav-module--link--39i23{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222;display:block;font-weight:400;padding:.5rem 1rem .5rem 2rem;text-decoration:none}.SubNav-module--link--39i23:focus{color:#222;outline:.25rem solid #0092a6;outline-offset:-.5rem}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222}.SubNav-module--link--39i23:hover{background:#d6d6d6;color:#222;text-decoration:underline}.SubNav-module--imageLink--3xwIS{display:none}@media(min-width:56.25em){.SubNav-module--wrapper--yAXWY{border-bottom:.125rem solid #004650;bottom:0;height:3rem;left:0;position:absolute;width:100%}.SubNav-module--imageLink--3xwIS{display:inline-block}.SubNav-module--list--1K9bK{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);height:100%}.SubNav-module--list--1K9bK li{display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23{border:0;display:block;height:100%;padding:0 1rem}.SubNav-module--link--39i23[aria-current=page],.SubNav-module--link--39i23[aria-current=true]{background:transparent}.SubNav-module--link--39i23[aria-current=page]:after,.SubNav-module--link--39i23[aria-current=true]:after{display:none}.SubNav-module--link--39i23:before{content:"";display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border:0}}.SubNav-module--image--uq-a2{height:100%}.Nav-module--link--3JzDA .Nav-module--tooltip--1Uj-W{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Nav-module--link--3JzDA:focus-visible .Nav-module--tooltip--1Uj-W{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Nav-module--visuallyHidden--ORHqX{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Nav-module--wrapper--2_xng{display:none;position:relative}@media print{.Nav-module--wrapper--2_xng{display:none!important}}@media(min-width:56.25em){.Nav-module--wrapper--2_xng{display:block}}.Nav-module--wrapperExpanded--3RxQB{display:block}.Nav-module--nav--2aQpa abbr[title]{border-bottom:0;cursor:help;text-decoration:none}.Nav-module--myAccount--3lsif{border-top:1px solid #fff}@media(min-width:56.25em){.Nav-module--myAccount--3lsif{display:none}}.Nav-module--myAccountHeading--1A5_B{border:.25rem solid #004650;font-size:100%;margin:0;padding:.5rem 1rem}.Nav-module--menuWrapper--2fp8S{background:#004650;color:#fff;padding:.25rem 0}.Nav-module--menuList--264L-{list-style:none;margin:auto;padding:0}.Nav-module--menuList--264L->li{margin:0}a.Nav-module--link--3JzDA{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#fff;display:block;font-weight:400;padding:.5rem 1rem;text-decoration:none}a.Nav-module--link--3JzDA span{text-decoration:inherit}a.Nav-module--link--3JzDA:focus{color:#fff;outline:.25rem solid #fff;outline-offset:-.5rem;z-index:1}a.Nav-module--link--3JzDA:visited{color:#fff}a.Nav-module--link--3JzDA:active{background:#acadad;color:#222}a.Nav-module--link--3JzDA:hover{background:#d6d6d6;color:#222;text-decoration:underline}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{background:#fff;color:#222;font-weight:700}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-color:#0092a6;outline-offset:-.25rem}@media(min-width:56.25em){.Nav-module--wrapperWithSubLinks--3PUfX{padding-bottom:3rem}.Nav-module--menuList--264L-{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);display:-webkit-flex;display:flex;-webkit-flex-direction:row;flex-direction:row;-webkit-flex-wrap:nowrap;flex-wrap:nowrap;-webkit-justify-content:space-between;justify-content:space-between}.Nav-module--menuList--264L->li{-webkit-flex-grow:1;flex-grow:1}a.Nav-module--link--3JzDA{border-left-width:0;border-right-width:0;display:-webkit-flex;display:flex;-webkit-flex-direction:column;flex-direction:column;height:100%;-webkit-justify-content:center;justify-content:center;line-height:1.25;margin:0;padding:.5rem;position:relative;text-align:center}a.Nav-module--link--3JzDA:focus{outline-offset:-.25rem}a.Nav-module--link--3JzDA span{display:inline-block;vertical-align:middle;white-space:normal}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{margin:0 .25rem}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-offset:-.5rem}a.Nav-module--link--3JzDA[aria-current=page]:after,a.Nav-module--link--3JzDA[aria-current=true]:after{background:#fff;content:"";display:block;height:.25rem;left:0;position:absolute;top:100%;width:100%}a.Nav-module--link--3JzDA[aria-current=page]:hover:after,a.Nav-module--link--3JzDA[aria-current=true]:hover:after{background:#d6d6d6}}@media(min-width:56.25em)and (min-width:75em){a.Nav-module--link--3JzDA{padding:1rem}}.Autocomplete-module--ac--2PqiF .autocomplete__wrapper{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input{-webkit-appearance:none;border:1px solid #222;border-radius:0;box-sizing:border-box;margin-bottom:0;width:100%}.Autocomplete-module--ac--2PqiF .autocomplete__input{background-color:#e9e9e9!important;height:2.5rem!important;margin:0!important;max-width:100%!important;position:relative;z-index:101}.Autocomplete-module--ac--2PqiF .autocomplete__input:focus{outline:3px solid #0092a6;outline-offset:-3px;z-index:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-webkit-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-moz-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input:-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__hint{color:#bfc1c3;position:absolute}.Autocomplete-module--ac--2PqiF .autocomplete__input--default{padding:.5rem}.Autocomplete-module--ac--2PqiF .autocomplete__input--focused{outline:3px solid #0092a6;outline-offset:-3px}.Autocomplete-module--ac--2PqiF .autocomplete__input--show-all-values{padding:4px 34px 4px 4px;cursor:pointer}.Autocomplete-module--ac--2PqiF .autocomplete__dropdown-arrow-down{z-index:-1;display:inline-block;position:absolute;right:8px;width:24px;height:24px;top:10px}.Autocomplete-module--ac--2PqiF .autocomplete__menu{background-color:#fff;border:1px solid #d6d6d6;border-top:0;color:#34384b;margin:0;max-width:100%;padding:0;text-align:left;width:-webkit-calc(100vw - 2rem);width:calc(100vw - 2rem)}@media(min-width:37.5em){.Autocomplete-module--ac--2PqiF .autocomplete__menu{width:100%}}.Autocomplete-module--ac--2PqiF .autocomplete__menu--visible{display:block}.Autocomplete-module--ac--2PqiF .autocomplete__menu--hidden{display:none}.Autocomplete-module--ac--2PqiF .autocomplete__menu--overlay{box-shadow:0 .25rem 1rem .25rem rgba(0,0,0,.1);left:0;position:absolute;top:100%;z-index:100}.Autocomplete-module--ac--2PqiF .autocomplete__menu--inline{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option{border-left-width:0;border-bottom:1px solid #d6d6d6;border-right-width:0;border-top-width:1px;color:#005ea5;cursor:pointer;display:block;margin:0;position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option a{color:inherit;display:block;font-weight:400;padding:.5rem;text-decoration:none}.Autocomplete-module--ac--2PqiF .autocomplete__option mark{background:0;color:inherit;font-weight:700;padding:0}.Autocomplete-module--ac--2PqiF .autocomplete__option>*{pointer-events:none}.Autocomplete-module--ac--2PqiF .autocomplete__option:first-of-type{border-top-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option:last-of-type{border-bottom-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option--odd{background-color:#fafafa}.Autocomplete-module--ac--2PqiF .autocomplete__option--focused,.Autocomplete-module--ac--2PqiF .autocomplete__option:hover{background-color:#e9e9e9;color:#005ea5;outline:none;text-decoration:underline}.Autocomplete-module--ac--2PqiF .autocomplete__option--no-results{background-color:#fafafa;color:#646b6f;cursor:not-allowed}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input,.Autocomplete-module--ac--2PqiF .autocomplete__option{font-size:16px;line-height:1.25}.Search-module--search--2wNll{margin:0;padding-right:2.5rem;position:relative}.Search-module--label--1rrog{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute!important;width:1px}.Search-module--button--2FbnI{background:#393939;border:0;color:#fff;cursor:pointer;height:2.5rem;min-width:2.5rem;padding:0 .5rem;position:absolute;right:0;text-align:center;top:0;z-index:101}.Search-module--button--2FbnI:focus{outline:.25rem solid #0092a6}.Search-module--button--2FbnI .Search-module--icon--2JB42{font-size:150%;vertical-align:middle}.Account-module--account--1BtRh{position:relative}.Account-module--button--zZii1{background:#fff;border:1px solid #222;color:#222;cursor:pointer;display:inline-block;font-family:inherit;font-size:inherit;font-weight:400;height:2.5rem;line-height:2.5rem;padding:0 .5rem;text-decoration:none;vertical-align:middle;white-space:nowrap}.Account-module--button--zZii1:focus{outline:.25rem solid #0092a6}.Account-module--button--zZii1:visited{color:#222}.Account-module--button--zZii1:hover{border:1px solid #222}.Account-module--myAccount--3jTaq:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Account-module--myAccount--3jTaq[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Account-module--menu--3C46i{background:#fff;border:1px solid #393939;list-style:none;margin:.625rem 0 0;padding:0;position:absolute;right:0;top:100%;z-index:2}.Account-module--menu--3C46i:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i[aria-hidden=true]{display:none}.Account-module--menu--3C46i:before{border-bottom:.5rem solid #393939;border-left:.25rem solid transparent;border-right:.25rem solid transparent}.Account-module--menu--3C46i:after,.Account-module--menu--3C46i:before{bottom:100%;content:"";display:block;height:0;position:absolute;right:1rem;width:0}.Account-module--menu--3C46i:after{border-bottom:.4rem solid #fff;border-left:.2rem solid transparent;border-right:.2rem solid transparent;margin-right:1px}.Account-module--menu--3C46i li{border-top:1px solid #d6d6d6;list-style:none;margin:0}.Account-module--menu--3C46i a{color:#005ea5;display:block;padding:.5rem 1rem;text-decoration:none;white-space:nowrap}.Account-module--menu--3C46i a:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i a:hover{background:#e9e9e9;text-decoration:underline}.Header-module--header--3os44{background:#fff;border-bottom:.125rem solid #004650;box-sizing:border-box;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif}.Header-module--header--3os44 *,.Header-module--header--3os44 :after,.Header-module--header--3os44 :before{box-sizing:inherit;font-family:inherit}@media print{.Header-module--header--3os44{border-bottom:none}}.Header-module--container--1mfIr{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0 0}.Header-module--container--1mfIr:after{clear:both;content:"";display:table}.Header-module--home--1TCPb{color:#000;display:inline-block;float:left;height:1.875rem;margin-bottom:1rem}@media print{.Header-module--home--1TCPb:after{content:none!important}}.Header-module--home--1TCPb:focus{outline:.25rem solid #0092a6}.Header-module--home--1TCPb:visited{color:#000}.Header-module--home--1TCPb .Header-module--icon--4LSt5{height:100%;width:auto}.Header-module--wrapper--2e13D{display:-webkit-flex;display:flex;-webkit-flex-grow:1;flex-grow:1;float:right;-webkit-justify-content:space-between;justify-content:space-between;margin-bottom:1rem;width:50%}@media print{.Header-module--wrapper--2e13D{display:none!important}}.Header-module--wrapper--2e13D:after{clear:both;content:"";display:table}.Header-module--search--2nfnz{-webkit-flex-grow:1;flex-grow:1;float:left;margin-right:1rem;min-width:66.6666666667%}.Header-module--mobileMenuBtn--1LgyL{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:1px solid #222;float:right;font-family:inherit;font-size:110%;height:2.5rem;min-width:4.6875rem;white-space:nowrap}.Header-module--mobileMenuBtn--1LgyL:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Header-module--mobileMenuBtn--1LgyL[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Header-module--account--y72Q4{display:none}@media(max-width:56.24em){.Header-module--home--1TCPb{float:none}.Header-module--wrapper--2e13D{float:none;width:auto}}@media(min-width:56.25em){.Header-module--header--3os44{border-bottom:.25rem solid #fff}.Header-module--container--1mfIr{display:-webkit-flex;display:flex;-webkit-justify-content:space-between;justify-content:space-between}.Header-module--home--1TCPb{height:2.5rem;margin-right:2rem}.Header-module--wrapper--2e13D{-webkit-justify-content:flex-end;justify-content:flex-end}.Header-module--search--2nfnz{margin-right:2rem}.Header-module--mobileMenuBtn--1LgyL{display:none}.Header-module--account--y72Q4{display:block}}.SkipLinks-module--list--1WwLa{list-style:none;margin:0;padding:0}@media print{.SkipLinks-module--list--1WwLa{display:none!important}}.SkipLinks-module--list--1WwLa li{list-style:none;margin:0}.SkipLinks-module--link--hkZw8{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.SkipLinks-module--link--hkZw8:focus{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;left:.25rem;outline:3px solid #0092a6;overflow:visible;padding:.5rem 1rem;position:absolute;top:.25rem;white-space:nowrap;width:auto;z-index:1}.Social-module--wrapper--2nKsd{clear:left}.Social-module--list--E5R5J{list-style:none;margin:0;max-width:100%;padding:0}.Social-module--list--E5R5J li{margin:0 0 .25rem}.Social-module--list--E5R5J svg{margin:-.125rem .25rem 0 0;vertical-align:middle}@media(min-width:37.5em){.Social-module--list--E5R5J li{float:left;margin:0 1rem 0 0}}@media(min-width:56.25em){.Social-module--wrapper--2nKsd{clear:none}.Social-module--wrapper--2nKsd li{float:none;margin:0 0 .25rem}}.Legal-module--wrapper--3AYMO{font-size:.875rem;line-height:1.25rem;background:#393939;padding:1rem 0}.Legal-module--wrapper--3AYMO a{text-decoration:underline}.Legal-module--container--3TTBh{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.Legal-module--menu--1e1Iy{margin:0 0 1rem}@media print{.Legal-module--menu--1e1Iy{display:none!important}}.Legal-module--menu--1e1Iy ul{list-style:none;margin:0;max-width:100%;padding:0}.Legal-module--menu--1e1Iy li{margin:0}.Legal-module--menu--1e1Iy a{display:block}.Legal-module--copyright--34nsI{font-size:.875rem;line-height:1.25rem;margin:0}@media print{.Legal-module--copyright--34nsI{float:none!important;max-width:100%}}@media(min-width:37.5em){.Legal-module--menu--1e1Iy li{display:inline-block;margin-right:1rem}}@media(min-width:75em){.Legal-module--wrapper--3AYMO:after,.Legal-module--wrapper--3AYMO:before{content:" ";display:table}.Legal-module--wrapper--3AYMO:after{clear:both}.Legal-module--menu--1e1Iy{float:left;margin:0}.Legal-module--copyright--34nsI{float:right}}.Services-module--link--2y_1q .Services-module--tooltip--pg3nW{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Services-module--link--2y_1q:focus-visible .Services-module--tooltip--pg3nW{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Services-module--visuallyHidden--t9mfm{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Services-module--wrapper--2qOoE{margin:0 0 2rem}.Services-module--list--3SZQu{list-style:none;margin:0;padding:0}.Services-module--list--3SZQu li{margin:0 0 .25rem}@media(min-width:37.5em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;width:33.3333333333%}}@media(min-width:56.25em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;margin:0;width:25%}}.Pages-module--wrapper--30REl{margin:0 0 2rem}.Pages-module--list--vvSk4{list-style:none;margin:0;padding:0}.Pages-module--list--vvSk4 li{margin:0 0 .25rem}@media(min-width:25em){.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}@media(min-width:37.5em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 0 0 2rem;width:66.6666666667%}}@media(min-width:56.25em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 2rem;width:50%}.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}.Footer-module--link--CGIYk .Footer-module--tooltip--1zoJv{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Footer-module--link--CGIYk:focus-visible .Footer-module--tooltip--1zoJv{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Footer-module--visuallyHidden--3CCnP{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Footer-module--footer--2QrGZ{background:#222;box-sizing:border-box;color:#fff;contain-intrinsic-size:350px;content-visibility:auto;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;margin:2rem 0 0}.Footer-module--footer--2QrGZ a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.Footer-module--footer--2QrGZ a:visited{color:#fff}.Footer-module--footer--2QrGZ a:hover{color:#d6d6d6}.Footer-module--footer--2QrGZ a:focus{outline:.25rem solid #fff;color:#fff}.Footer-module--footer--2QrGZ a:active{color:#d6d6d6}.Footer-module--footer--2QrGZ *,.Footer-module--footer--2QrGZ :after,.Footer-module--footer--2QrGZ :before{box-sizing:inherit}.Footer-module--footer--2QrGZ a{font-weight:400}.Footer-module--container--1iuoB{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0}.Footer-module--container--1iuoB:after,.Footer-module--container--1iuoB:before{content:" ";display:table}.Footer-module--container--1iuoB:after{clear:both}@media print{.Footer-module--container--1iuoB{display:none!important}}.Footer-module--logo--3DGKv{display:block;height:0;margin:0 0 2rem;padding:0 0 29.0496453901px;position:relative;width:80px}.Footer-module--logo--3DGKv svg{display:block;height:100%!important;left:0;position:absolute;top:0;width:100%!important}@media(min-width:56.25em){.Footer-module--logo--3DGKv{margin-bottom:1rem}}.BackToTop-module--wrapper--2Z0EU{margin-top:3rem}@media print{.BackToTop-module--wrapper--2Z0EU{display:none}}.BackToTop-module--nav--1DPZ6{background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}.BackToTop-module--anchor--1Nia6{display:block;line-height:1rem;padding:1rem 0}.BackToTop-module--anchor--1Nia6:visited{color:#005ea5}.BackToTop-module--anchor--1Nia6 svg{-webkit-transition:all .25s ease;transition:all .25s ease}.BackToTop-module--anchor--1Nia6:hover{background:#f4f4f4}.BackToTop-module--anchor--1Nia6:hover svg{-webkit-transform:translateY(-.125rem);transform:translateY(-.125rem)}@supports((position:-webkit-sticky) or (position:sticky)){.BackToTop-module--wrapper--2Z0EU{bottom:0;left:0;margin:0;pointer-events:none;position:absolute;right:0;top:min(100vh,-webkit-calc(100% - 3rem));top:min(100vh,calc(100% - 3rem));width:100%;z-index:99}.BackToTop-module--nav--1DPZ6{position:-webkit-sticky;position:sticky;pointer-events:all;top:-webkit-calc(100vh - 3rem);top:calc(100vh - 3rem);background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-regular.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-regular.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:italic;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-italic.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-italic.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:700;src:local("Lato"),url(../../../../fonts/lato-v17-latin-700.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-700.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:900;src:local("Lato"),url(../../../../fonts/lato-v17-latin-900.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-900.woff) format("woff")}/*! normalize.css v8.0.1 | MIT License | github.com/necolas/normalize.css */html{line-height:1.15;-webkit-text-size-adjust:100%}body{margin:0}main{display:block}h1{font-size:2em;margin:.67em 0}hr{box-sizing:content-box;height:0;overflow:visible}pre{font-family:monospace,monospace;font-size:1em}a{background-color:transparent}abbr[title]{border-bottom:none;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}b,strong{font-weight:bolder}code,kbd,samp{font-family:monospace,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}img{border-style:none}button,input,optgroup,select,textarea{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}[type=button]:-moz-focusring,[type=reset]:-moz-focusring,[type=submit]:-moz-focusring,button:-moz-focusring{outline:1px dotted ButtonText}fieldset{padding:.35em .75em .625em}legend{box-sizing:border-box;color:inherit;display:table;max-width:100%;padding:0;white-space:normal}progress{vertical-align:baseline}textarea{overflow:auto}[type=checkbox],[type=radio]{box-sizing:border-box;padding:0}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}details{display:block}summary{display:list-item}[hidden],template{display:none}.show-print{display:none!important}@media print{.show-print{display:block!important}}@media print{.hide-print{display:none!important}}@media print{.remove-appended-print-link:after{content:none!important}}@media print{*{background:transparent!important;box-shadow:none!important;color:#000!important;text-shadow:none!important}a,a:visited{text-decoration:underline}}@media print{h1 a:after,h2 a:after,h3 a:after,h4 a:after,h5 a:after,h6 a:after{content:none!important}}@media print{a[href]:after{content:" (" attr(href) ")"}}@media print{abbr[title]:after{content:" (" attr(title) ")"}}@media print{.ir a:after,a[href^="#"]:after,a[href^="javascript:"]:after{content:""}}@media print{blockquote,pre{border:1px solid #999;page-break-inside:avoid}}@media print{thead{display:table-header-group}}@media print{img,tr{page-break-inside:avoid}}@media print{img{max-width:100%!important}}@media print{img:not([alt]),img[alt=""]{display:none!important}}@media print{@page{margin:.5cm}}@media print{h2,h3,p{orphans:3;widows:3}}@media print{h2,h3{page-break-after:avoid}}.clearfix:after,.clearfix:before{content:" ";display:table}.clearfix:after{clear:both}.container{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.container--full{max-width:100%;padding:0 2%;width:auto}html{box-sizing:border-box;font-size:.9375rem;overflow-x:hidden}html *,html :after,html :before{box-sizing:inherit}@media(min-width:56.25em){html{font-size:1.03125rem;font-size:-webkit-calc(.375rem + 1vw);font-size:calc(.375rem + 1vw)}}@media(min-width:75em){html{font-size:1.125rem}}body{background:#f4f4f4;color:#222;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;font-style:normal;line-height:1.5rem;overflow-x:hidden;text-rendering:optimizelegibility}img{max-width:100%}hr{background:0;border:0;border-top:.0625em solid #adadad;margin:2em 0;padding:0}.p,p{font-size:1rem;line-height:1.5rem;font-feature-settings:"kern","onum","liga"}.lead,.p,p{margin-bottom:1rem;margin-top:1rem;font-weight:400;max-width:66ch}.lead{font-size:1.25rem;line-height:1.75rem}code{background:#e9e9e9;border:1px solid #adadad;border-radius:.125em;color:#222;display:inline-block;font-family:Monaco,Menlo,Consolas,Courier New,monospace;margin:0 0 .125em;padding:0 .25em}pre code{background:transparent;border:0;margin:0}.mark,mark{background-color:#fff999;padding:0 .25em}.small,small{font-size:85%}.h6,h6{font-size:1rem}.h5,.h6,h5,h6{line-height:1.5rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h5,h5{font-size:1.125rem}.h4,h4{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h3,h3{font-size:1.75rem;line-height:2rem}.h2,.h3,h2,h3{margin-bottom:1rem;margin-top:2rem;clear:both;font-weight:700;max-width:66ch}.h2,h2{font-size:2.25rem;line-height:2.5rem}.h1,.h2+.h3,.h2+h3,h1,h2+.h3,h2+h3{margin-top:0}.h1,h1{font-size:2.75rem;line-height:3.5rem;margin-bottom:1rem;clear:both;font-weight:900;max-width:66ch}.h1+.h2,.h1+h2,h1+.h2,h1+h2{margin-top:0}a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}a:visited{color:#4c2c92}a:hover{color:#2e8aca}a:focus{outline:.25rem solid #0092a6;color:#005ea5}a:active{color:#222}.link--inverse{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.link--inverse:visited{color:#fff}.link--inverse:hover{color:#d6d6d6}.link--inverse:focus{outline:.25rem solid #fff;color:#fff}.link--inverse:active{color:#d6d6d6}.inverse-links a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.inverse-links a:visited{color:#fff}.inverse-links a:hover{color:#d6d6d6}.inverse-links a:focus{outline:.25rem solid #fff;color:#fff}.inverse-links a:active{color:#d6d6d6}.list,ol,ul{font-feature-settings:"kern","onum","liga";margin-left:1rem;max-width:66ch;padding:0}.list--unstyled{list-style:none;margin-left:0;max-width:none;padding:0}.list--loose .list__item,.list--loose li{margin-bottom:.25rem}.list--piped{list-style:none;margin-left:0;padding:0}.list--piped .list__item,.list--piped li{display:inline-block;margin-right:-.25rem}.list--piped .list__item a,.list--piped li a{padding:.5rem}.list--piped .list__item:after,.list--piped li:after{border-left:1px solid #004650;content:"\200B";display:inline-block;margin:0 .5em;overflow:hidden;text-indent:-99px;vertical-align:middle;width:0}.list--piped .list__item:first-child a,.list--piped li:first-child a{padding-left:0}.list--piped .list__item:last-child:after,.list--piped li:last-child:after{display:none}.quote{font-size:1.25rem;line-height:1.75rem;border-left:.25em solid #004650;font-weight:400;margin:2rem 0;padding:0 0 0 4rem;position:relative}.quote:before{color:#004650;content:"\201C";display:block;font-family:Arial,sans-serif;font-size:5rem;font-weight:700;left:0;line-height:.8;position:absolute;text-align:center;top:0;width:4rem}@media print{.quote:before{color:#000}}.quote p{font-size:inherit}.quote cite,.quote footer{font-size:1rem;line-height:1.5rem;font-style:normal}table{background:#fff;border:1px solid #adadad;border-collapse:collapse;display:block;margin:0 0 1rem;max-width:100%;overflow-y:hidden;overflow-x:auto;width:100%!important}table th{vertical-align:bottom}table td{vertical-align:top}table td,table th{border:1px solid #adadad;padding:.5rem;text-align:left}table td:first-child,table th:first-child{border-left:0}table td:last-child,table th:last-child{border-right:0}table td p,table th p{margin-top:0}table :not(thead)+tbody tr:first-child th,table tbody tr:first-child th,table thead tr:first-child th{border-top:0}table tbody tr:last-child td{border-bottom:0}table tbody tr:nth-child(2n)>td{background-color:#e9e9e9}html{overflow-x:visible;scroll-behavior:smooth}@media(prefers-reduced-motion){html{scroll-behavior:auto}}body{font-family:Lato,Trebuchet MS,Roboto,Helvetica Neue,Helvetica,Arial,sans-serif;position:relative}.visually-hidden{position:absolute;overflow:hidden;clip:rect(0 0 0 0);height:1px;width:1px;margin:-1px;padding:0;border:0}#content-start:focus{outline:none}footer{margin-top:0!important}@supports((position:-webkit-sticky) or (position:sticky)){.Layout-module--main--1OIFf{position:relative;padding-bottom:4rem}}.stacked-nav{background:#fff;border:1px solid #adadad;margin:0 0 2em}@media print{.stacked-nav{display:none!important}}.stacked-nav__root{font-size:1rem;line-height:1.5rem;border-bottom:1px solid #adadad;font-weight:700;margin:0;max-width:none;position:relative;text-decoration:none}.stacked-nav__root a{color:#222}.stacked-nav__root--no-link{padding:.5em}.stacked-nav__hint{color:#222;display:block}.stacked-nav__hint :active{color:#fff}.stacked-nav__list{list-style:none;margin:0;max-width:100%;padding:0}.stacked-nav__list-item{border-top:1px solid #adadad}.stacked-nav__content-wrapper{display:block}.stacked-nav a{color:#005ea5;display:block;padding:.5em;position:relative;text-decoration:none}.stacked-nav a[aria-current=page],.stacked-nav a[aria-current=true]{background:#e9e9e9;font-weight:700}.stacked-nav a[aria-current=page]:before,.stacked-nav a[aria-current=true]:before{background:#004650;content:"";display:block;height:100%;left:0;position:absolute;top:0;width:.25em}.stacked-nav a:hover{background:#d6d6d6}.stacked-nav a:active{background:#004650;color:#fff}.stacked-nav a:active span{color:#fff}.stacked-nav__nested{list-style:none;margin:0;padding:0}.stacked-nav__nested .stacked-nav__content-wrapper{padding-left:1rem!important}.stacked-nav__nested ul .stacked-nav__content-wrapper{padding-left:2rem!important}.TopicChaptersMenu-module--toggleButton--2MGXA{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:#e9e9e9;border:1px solid #adadad;color:#005ea5;cursor:pointer;display:block;margin:0 0 2rem;padding:1rem 2rem 1rem .5rem;position:relative;text-align:left;width:100%}.TopicChaptersMenu-module--toggleButton--2MGXA:focus{outline:.25rem solid #0092a6;z-index:1}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=false]+.stacked-nav{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]{border-bottom:0;margin:0}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]+.stacked-nav{display:block}@media(min-width:37.5em){.TopicChaptersMenu-module--toggleButton--2MGXA{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded]+.stacked-nav{display:block}}.TopicChaptersMenu-module--icon--27uSj{color:#005ea5;right:.5rem;position:absolute;top:50%;-webkit-transform:translateY(-50%);transform:translateY(-50%)}.ChapterContents-module--wrapper--3ONbu{position:relative}.ChapterContents-module--printBtn--Rk_Zs{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;bottom:100%;cursor:pointer;display:none;padding:0}.ChapterContents-module--printBtn--Rk_Zs:visited{color:#4c2c92}.ChapterContents-module--printBtn--Rk_Zs:hover{color:#2e8aca}.ChapterContents-module--printBtn--Rk_Zs:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterContents-module--printBtn--Rk_Zs:active{color:#222}.ChapterContents-module--printBtn--Rk_Zs svg{font-size:1.25rem;line-height:1.75rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterContents-module--printBtn--Rk_Zs:hover svg{color:#2e8aca}@media(min-width:37.5em){.ChapterContents-module--wrapper--3ONbu:after,.ChapterContents-module--wrapper--3ONbu:before{content:" ";display:table}.ChapterContents-module--wrapper--3ONbu:after{clear:both}.ChapterContents-module--menu--3Epka{float:left;margin-right:1rem;width:-webkit-calc(25% - .5rem);width:calc(25% - .5rem)}.ChapterContents-module--landing--3klSq,.ChapterContents-module--onThisPage--1333P{float:right;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + .5rem);overflow:hidden;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}}@media(min-width:56.25em){.ChapterContents-module--printBtn--Rk_Zs{display:block;margin-bottom:3rem;position:absolute;right:0}.ChapterContents-module--menu--3Epka{margin-right:2rem;width:-webkit-calc(25% - 1rem);width:calc(25% - 1rem)}.ChapterContents-module--landing--3klSq{width:-webkit-calc(75% - 1rem);width:calc(75% - 1rem)}.ChapterContents-module--onThisPage--1333P{position:-webkit-sticky;position:sticky;top:0;width:-webkit-calc(16.66667% - 1rem);width:calc(16.66667% - 1rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + 1rem);width:-webkit-calc(58.33333% - 2rem);width:calc(58.33333% - 2rem)}}@media print{.ChapterContents-module--menu--3Epka,.ChapterContents-module--onThisPage--1333P,.ChapterContents-module--printBtn--Rk_Zs{display:none}.ChapterContents-module--body--1XBoo{width:100%}}.ChapterBody-module--wrapper--2HCfk>.visually-hidden:first-child+*>:first-child{margin-top:0}.ChapterBody-module--wrapper--2HCfk h2:focus,.ChapterBody-module--wrapper--2HCfk h3:focus,.ChapterBody-module--wrapper--2HCfk h4:focus,.ChapterBody-module--wrapper--2HCfk h5:focus,.ChapterBody-module--wrapper--2HCfk h6:focus{outline:0!important}.ChapterBody-module--basisWrapper--3JBM_{border:1px solid #adadad;margin-top:1rem;max-width:66ch}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-top:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK{padding:0 1rem 1rem}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK>:last-child{margin-bottom:0}.ChapterBody-module--headerWrapper--qSIFw{padding:1rem;position:relative}.ChapterBody-module--toggleBtn--3g0p7{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;cursor:pointer;display:block;margin-top:-.5rem;padding:0}.ChapterBody-module--toggleBtn--3g0p7:visited{color:#4c2c92}.ChapterBody-module--toggleBtn--3g0p7:hover{color:#2e8aca}.ChapterBody-module--toggleBtn--3g0p7:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterBody-module--toggleBtn--3g0p7:active{color:#222}.ChapterBody-module--toggleBtn--3g0p7:after{content:"";height:100%;left:0;position:absolute;top:0;width:100%}.ChapterBody-module--toggleBtn--3g0p7 svg{font-size:1.125rem;line-height:1.5rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterBody-module--toggleBtn--3g0p7:hover svg{color:#2e8aca}.ChapterBody-module--body--2n0CK[aria-hidden=true]{display:none}@media print{.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-bottom:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK[aria-hidden=true]{display:block}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--toggleBtn--3g0p7{display:none}}.ChapterOnThisPage-module--wrapper--2zc7n{margin-bottom:2rem}.ChapterOnThisPage-module--heading--2SdDN{margin-top:0}.ChapterOnThisPage-module--rootList--2II70{list-style:disc}.ChapterOnThisPage-module--subList--Pwxy9{list-style:circle}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:none}@media(min-width:56.25em){.ChapterOnThisPage-module--heading--2SdDN{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:0}@supports((position:-webkit-sticky) or (position:sticky)){.ChapterOnThisPage-module--rootList--2II70 a[aria-current=location]{font-weight:700}.ChapterOnThisPage-module--rootList--2II70 a:focus+.ChapterOnThisPage-module--subList--Pwxy9{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--subList--Pwxy9{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.ChapterOnThisPage-module--subList--Pwxy9:focus-within{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--expandedSubList--1m1WN{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:list-item}}}</style><link rel="sitemap" type="application/xml" href="../../../../sitemap.xml"/><title data-react-helmet="true">Scenario: Management | Management | Contraception - emergency | CKS | NICE</title><link data-react-helmet="true" rel="search" type="application/opensearchdescription+xml" href="../../../../opensearch.xml" title="CKS"/><link data-react-helmet="true" rel="icon" href="../../../../favicon.ico"/><link data-react-helmet="true" rel="canonical" href="index.html"/><meta data-react-helmet="true" name="description" content="Covers advice on providing emergency contraception to prevent unintended pregnancy after unprotected sexual intercourse or contraceptive failure."/><meta data-react-helmet="true" property="og:description" content="Covers advice on providing emergency contraception to prevent unintended pregnancy after unprotected sexual intercourse or contraceptive failure."/><meta data-react-helmet="true" property="og:url" content="https://cks.nice.org.uk/topics/contraception-emergency/management/management/"/><meta data-react-helmet="true" property="og:locale" content="en_GB"/><meta data-react-helmet="true" property="og:type" content="website"/><meta data-react-helmet="true" property="og:title" content="Scenario: Management | Management | Contraception - emergency | CKS | NICE"/><meta data-react-helmet="true" property="og:image" content="https://cks.nice.org.uk/open-graph-image.png"/><meta data-react-helmet="true" property="og:image:width" content="1200"/><meta data-react-helmet="true" property="og:image:height" content="630"/><meta data-react-helmet="true" name="twitter:card" content="summary"/><meta data-react-helmet="true" name="twitter:image" content="https://cks.nice.org.uk/twitter-summary-image.png"/><meta data-react-helmet="true" name="twitter:image:alt" content="NICE and CKS logos"/><meta data-react-helmet="true" name="twitter:site" content="@NICEcomms"/><meta data-react-helmet="true" name="twitter:creator" content="@NICEcomms"/><meta data-react-helmet="true" name="theme-color" content="#004650"/><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+'';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer', 'GTM-54QC4NL');</script><link rel="manifest" href="../../../../manifest.webmanifest" crossorigin="anonymous"/><meta name="theme-color" content="#004650"/><link rel="apple-touch-icon" sizes="48x48" href="../../../../icons/icon-48x48.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="72x72" href="../../../../icons/icon-72x72.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="96x96" href="../../../../icons/icon-96x96.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="144x144" href="../../../../icons/icon-144x144.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="192x192" href="../../../../icons/icon-192x192.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="256x256" href="../../../../icons/icon-256x256.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="384x384" href="../../../../icons/icon-384x384.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="512x512" href="../../../../icons/icon-512x512.png@v=28734348209eeeae5c03a37867f1beb1"/><link as="script" rel="preload" href="../../../../webpack-runtime-28c424ef71f39faedaf0.js"/><link as="script" rel="preload" href="../../../../framework-34da02e39e1f104d9937.js"/><link as="script" rel="preload" href="../../../../app-53a71c38b210970893c4.js"/><link as="script" rel="preload" href="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js"/><link as="script" rel="preload" href="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js"/><link as="script" rel="preload" href="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"/><link as="fetch" rel="preload" href="../../../../page-data/topics/contraception-emergency/management/management/page-data.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/sq/d/3666801979.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/app-data.json" crossorigin="anonymous"/><script src="https://cdn.nice.org.uk/cookie-banner/cookie-banner.min.js" type="text/javascript" async=""></script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54QC4NL" height="0" width="0" style="display: none; visibility: hidden" aria-hidden="true"></iframe></noscript><div id="___gatsby"><div style="outline:none" tabindex="-1" id="gatsby-focus-wrapper"><div><div class="Header-module--header--3os44"><header aria-label="Site header"><ul class="SkipLinks-module--list--1WwLa" aria-label="Accessibility links"><li><a href="index.html#content-start" class="SkipLinks-module--link--hkZw8">Skip to content</a></li><li><a href="https://www.nice.org.uk/accessibility" class="SkipLinks-module--link--hkZw8">Accessibility help</a></li></ul><div class="Header-module--container--1mfIr"><a href="https://www.nice.org.uk/" aria-label="Home" class="Header-module--home--1TCPb"><svg viewBox="0 0 4616 512" fill="none" class="Header-module--icon--4LSt5" aria-hidden="true" focusable="false"><path d="M1626 44v175h-22L1497 71v148h-19V44h22l107 147V44h19zm130 154a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-35 18-48 11-14 27-20 47-20 19 0 34 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm109 16V104h-27V87h27V40h19v47h30v17h-30v115h-19zm88-180v26h-21V39h21zm-20 48h20v132h-20V87zm107-2c20 0 35 6 48 20 11 12 17 28 17 48 0 19-6 36-17 48a61 61 0 01-48 20c-19 0-35-7-47-20a69 69 0 01-17-48c0-20 5-36 17-48 12-14 28-20 47-20zm0 118c14 0 25-5 34-15 7-9 11-21 11-35s-4-26-11-35c-9-10-20-15-34-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm107-116v21c5-7 11-12 18-17 6-4 14-6 23-6 8 0 16 1 22 4 6 2 12 6 17 11 10 10 16 24 16 42v77h-20v-76c0-13-3-22-10-29-7-8-16-11-26-11a38 38 0 00-40 40v76h-19V87h19zm222 111a52 52 0 01-46 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 5-35 17-48 12-14 27-20 47-20 19 0 35 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm114 16h-19V34h19v185zm108 0h-19V44h19v175zm55-132v21c5-7 10-12 17-17 7-4 15-6 23-6 9 0 17 1 23 4 6 2 12 6 16 11 11 10 16 24 16 42v77h-19v-76c0-13-4-22-10-29-7-8-16-11-27-11a38 38 0 00-39 40v76h-19V87h19zm202 35c-2-13-13-20-33-20s-30 6-30 19c0 5 2 9 6 12 5 2 10 5 16 6l21 5 21 7c7 2 12 6 16 11 5 5 7 11 7 19 0 13-5 23-15 30-9 7-22 10-38 10-18 0-32-4-42-13-9-8-14-18-15-31h20c2 13 8 21 21 25l13 2 13-1 11-3c8-3 12-9 12-17 0-5-2-9-6-12s-10-6-16-7l-21-5-21-7c-7-2-12-6-16-10-4-5-6-11-6-19 0-12 4-22 12-28 9-7 22-10 39-10 15 0 28 4 37 11 8 7 12 16 14 26h-20zm60 97V104h-26V87h26V40h20v47h30v17h-30v115h-20zm89-180v26h-21V39h21zm-21 48h20v132h-20V87zm65 132V104h-26V87h26V40h20v47h30v17h-30v115h-20zm162 0v-21c-4 7-10 12-17 16-7 5-14 7-23 7s-16-1-22-4c-7-2-12-6-17-11a57 57 0 01-16-42V87h20v76c0 12 3 22 10 29 6 7 15 11 26 11a39 39 0 0039-40V87h20v132h-20zm65 0V104h-26V87h26V40h20v47h30v17h-30v115h-20zm124-16c17 0 30-7 37-22h22c-5 12-12 22-22 29-9 7-22 11-38 11-19 0-35-7-47-20a68 68 0 01-18-48c0-20 5-36 17-48 12-14 28-20 47-20 20 0 35 6 48 20 11 12 17 28 17 48v8h-109c1 12 6 22 14 30s19 12 32 12zm-2-100c-12 0-22 4-30 11s-12 17-14 28h88c-1-11-6-21-14-28s-18-11-30-11zm195-52c-9 0-16 2-21 6-4 4-7 11-7 20v10h30v17h-30v115h-19V104h-23V87h23V75c0-14 4-25 12-32 9-7 21-11 36-11h1v19h-2zm75 34c19 0 35 6 47 20 12 12 18 28 18 48 0 19-6 36-18 48a61 61 0 01-47 20c-19 0-35-7-47-20a69 69 0 01-18-48c0-20 6-36 18-48 12-14 28-20 47-20zm0 118c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm156-118v20h-2c-14 0-25 5-34 17-9 11-13 24-13 39v58h-19V87h19v32c4-13 13-23 27-30 6-3 13-4 21-4h1zM1617 293v175h-19v-78h-101v78h-19V293h19v78h101v-78h19zm91 159c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c1 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm187 95a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-36 18-49 11-13 27-19 47-19 19 0 34 7 45 23v-21h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm114 16h-19V283h19v185zm46 0V353h-27v-17h27v-48h19v48h30v17h-30v115h-19zm87-185v73l17-16c7-4 15-6 24-6 8 0 16 1 22 3a58 58 0 0133 54v77h-20v-77c0-12-3-21-10-29-7-7-16-10-26-10a39 39 0 00-40 40v76h-19V283h19zm280 164a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm109-116v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 11 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10a39 39 0 00-39 40v76h-19V336h19zm222 111a52 52 0 01-47 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-74h19v185h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm233-1a56 56 0 0053-36h21c-6 17-15 30-28 39a82 82 0 01-50 16c-25 0-46-9-61-26a92 92 0 01-22-64c0-25 7-46 22-63 15-18 36-26 61-26a78 78 0 0178 54h-21c-4-11-11-19-20-25-10-7-20-10-33-10-12 0-22 2-30 5-9 4-15 9-21 15a73 73 0 00-17 50c0 21 6 37 17 50 12 14 29 21 51 21zm198-4a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 48-19 19 0 34 7 45 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm163-118v19h-2c-14 0-26 6-34 18-9 10-13 23-13 39v58h-19V336h19v32c4-14 13-24 27-30 6-3 13-4 21-4h1zm73 118c18 0 31-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-19 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 18-49s27-19 47-19c19 0 35 6 47 19s17 29 17 49v8h-109c2 12 7 22 15 30s19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm162-40v59h96v19h-96v59h108v19h-127V293h127v19h-108zm189 88l51 68h-25l-37-54-37 54h-25l51-68-48-64h25l34 50 33-50h25l-47 64zm120 52c9 0 16-3 23-7 6-5 11-11 14-19h21c-4 13-12 24-22 32-11 8-24 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19a60 60 0 0161 44h-20c-3-8-8-15-14-19-7-5-14-7-23-7-8 0-15 1-21 4-6 2-10 6-14 10-9 10-13 22-13 36s4 26 13 35c8 10 20 15 35 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-20 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 13-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm105 116h-19V283h19v185zm51 0h-20V283h20v185zm89-16c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c2 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm105-16v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 12 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10s-20 3-28 11c-7 7-11 17-11 29v76h-19V336h19zm185 116a40 40 0 0037-26h21c-4 13-12 24-22 32-11 8-25 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19c15 0 29 4 40 12 10 8 18 18 22 31h-21c-3-7-8-14-15-18-6-5-13-7-22-7-8 0-15 1-21 4-6 2-11 6-15 10-8 10-12 22-12 36s4 26 12 35c9 10 21 15 36 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 18 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-15 28h89c-2-11-6-21-14-28-8-8-18-11-30-11zM412 454c0 16-7 19-18 19h-53c-11 0-20-4-27-13L130 213h-2v242c0 13-6 18-18 18H52c-14 0-20-3-20-18V62c0-16 7-19 20-19h52c13 0 19 3 26 13l184 248h1V61c0-14 7-18 19-18h60c16 0 17 8 17 19v392h1zm197 4c0 7-5 14-14 14h-71c-9 0-14-7-14-14V56c0-8 5-15 14-15h71c9 0 14 7 14 14v403zm415-380l-18 52c-2 6-5 9-9 9l-8-2c-33-16-58-21-87-21-65 0-106 49-106 140 0 98 47 140 107 140 29 0 55-5 84-17l9-3c6 0 9 3 11 10l16 46 2 10c0 6-3 11-12 14-42 16-77 24-125 24-131 0-197-87-197-221S772 32 896 32c45 0 82 9 118 25 9 4 12 8 12 12l-2 9zm336-37c13 0 17 6 16 15l-6 50c-1 13-9 15-24 15h-149v93h140c14 0 19 7 19 17v45c0 12-7 18-18 18h-141v98h161c11 0 18 5 18 17v46c0 11-6 17-17 17h-240c-14 0-21-4-21-19V59c0-11 6-18 16-18h246z" fill="currentColor"></path></svg></a><div class="Header-module--wrapper--2e13D"><div class="Header-module--search--2nfnz"><form id="global-nav-search-form" role="search" action="https://cks.nice.org.uk/search" class="Search-module--search--2wNll"><label class="Search-module--label--1rrog" for="autocomplete">Search CKS…</label><div class="Autocomplete-module--ac--2PqiF"><div class="autocomplete__wrapper"><input type="search" id="autocomplete" name="q" class="autocomplete__input autocomplete__input--default" placeholder="Search CKS…" data-hj-allow="" maxLength="512" value=""/></div></div><button class="Search-module--button--2FbnI" type="submit" aria-label="Perform search"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="Search-module--icon--2JB42" aria-hidden="true" focusable="false"><path d="M83.784 476.472L197.112 363.16c30.144 20.32 65.056 30.528 100.032 30.528 45.904 0 91.776-17.488 126.8-52.528 70.064-70.064 70.064-183.584 0-253.616C388.936 52.504 343.048 35 297.144 35c-45.904 0-91.808 17.504-126.848 52.528-61.696 61.696-68.976 157.12-21.968 226.864L35 427.752l48.784 48.72zm213.36-137.952c-33.168 0-64.352-12.896-87.792-36.368-48.416-48.448-48.416-127.2 0-175.616 23.44-23.44 54.64-36.352 87.792-36.352s64.336 12.912 87.776 36.368c23.44 23.456 36.384 54.64 36.384 87.792s-12.928 64.352-36.384 87.792c-23.456 23.472-54.624 36.368-87.776 36.368v.016z" fill="currentColor"></path></svg></button></form></div><button class="Header-module--mobileMenuBtn--1LgyL" id="header-menu-button" type="button" aria-controls="header-menu" aria-expanded="false" aria-haspopup="menu" aria-label="Expand site menu">Menu</button></div></div><div id="header-menu" class="Nav-module--wrapper--2_xng Nav-module--wrapperWithSubLinks--3PUfX"><nav class="Nav-module--nav--2aQpa" aria-label="primary navigation"><div class="Nav-module--menuWrapper--2fp8S"><ul class="Nav-module--menuList--264L-" aria-labelledby="header-menu-button"><li><a href="https://pathways.nice.org.uk/" class="Nav-module--link--3JzDA">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Nav-module--link--3JzDA">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Nav-module--link--3JzDA">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Nav-module--link--3JzDA">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary">BNF<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Nav-module--link--3JzDA"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">Clinical Knowledge Summaries</span></a><div class="SubNav-module--wrapper--yAXWY"><ul class="SubNav-module--list--1K9bK" aria-label="CKS links"><li class="SubNav-module--imageLink--3xwIS"><a href="../../../../index.html" class="SubNav-module--link--39i23" aria-label="CKS - Home"><img src="data:image/svg+xml;base64,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" class="SubNav-module--image--uq-a2" alt=""/></a></li><li><a href="../../../index.html" class="SubNav-module--link--39i23" aria-label="Health topics A to Z">Health topics A to Z</a></li><li><a href="../../../../specialities/index.html" class="SubNav-module--link--39i23" aria-label="Specialities">Specialities</a></li><li><a href="../../../../whats-new/index.html" class="SubNav-module--link--39i23" aria-label="What&#x27;s new">What&#x27;s new</a></li><li><a href="../../../../about/index.html" class="SubNav-module--link--39i23" aria-label="About CKS">About CKS</a></li></ul></div></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Nav-module--link--3JzDA">Journals and databases</a></li></ul></div></nav></div></header><aside class="CoronaMessage-module--wrapper--zRiaV" aria-label="COVID-19 Notice"><div class="CoronaMessage-module--container--36Biz"><p>Read about<!-- --> <a href="https://www.nice.org.uk/covid-19">our approach to COVID-19</a></p></div></aside></div></div><main class="Layout-module--main--1OIFf" id="content-start"><div class="container"><nav aria-label="Breadcrumbs" role="navigation"><ol class="breadcrumbs"><li class="breadcrumbs__crumb"><a href="https://www.nice.org.uk/">NICE</a></li><li class="breadcrumbs__crumb"><a href="../../../../index.html">CKS</a></li><li class="breadcrumbs__crumb"><a href="../../../index.html">Health topics A to Z</a></li><li class="breadcrumbs__crumb"><a href="../../index.html">Contraception - emergency</a></li><li class="breadcrumbs__crumb"><a href="../index.html">Management</a></li><li class="breadcrumbs__crumb"><span>Scenario: Management</span></li></ol></nav><script type="application/ld+json">{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.nice.org.uk/","name":"NICE"}},{"@type":"ListItem","position":2,"item":{"@id":"/","name":"CKS"}},{"@type":"ListItem","position":3,"item":{"@id":"/topics/","name":"Health topics A to Z"}},{"@type":"ListItem","position":4,"item":{"@id":"/topics/contraception-emergency/","name":"Contraception - emergency"}},{"@type":"ListItem","position":5,"item":{"@id":"/topics/contraception-emergency/management/","name":"Management"}},{"@type":"ListItem","position":6,"item":{"name":"Scenario: Management"}}]}</script><div class="page-header"><h1 class="page-header__heading"><span class="page-header__pre-heading">Contraception - emergency: </span><span>Scenario: Emergency hormonal contraception</span></h1><p class="page-header__lead"><span>February 2021</span></p></div><p class="visually-hidden">Covers advice on providing emergency contraception to prevent unintended pregnancy after unprotected sexual intercourse or contraceptive failure.</p><div class="ChapterContents-module--wrapper--3ONbu"><div class="ChapterContents-module--menu--3Epka"><nav class="stacked-nav" aria-label="Contraception - emergency chapters"><ul class="stacked-nav__list"><li class="stacked-nav__list-item" data-tracking="Summary"><a aria-current="false" href="../../index.html"><span class="stacked-nav__content-wrapper">Summary</span></a></li><li class="stacked-nav__list-item" data-tracking="Have I got the right topic?"><a aria-current="false" href="../../have-i-got-the-right-topic/index.html"><span class="stacked-nav__content-wrapper">Have I got the right topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="How up-to-date is this topic?"><a aria-current="false" href="../../how-up-to-date-is-this-topic/index.html"><span class="stacked-nav__content-wrapper">How up-to-date is this topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="Goals and outcome measures"><a aria-current="false" href="../../goals-outcome-measures/index.html"><span class="stacked-nav__content-wrapper">Goals and outcome measures</span></a></li><li class="stacked-nav__list-item" data-tracking="Background information"><a aria-current="false" href="../../background-information/index.html"><span class="stacked-nav__content-wrapper">Background information</span></a></li><li class="stacked-nav__list-item" data-tracking="Management"><a aria-current="false" href="../index.html"><span class="stacked-nav__content-wrapper">Management</span></a><ul class="stacked-nav__nested"><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Management"><a aria-current="true" class="" href="index.html"><span class="stacked-nav__content-wrapper">Scenario: Management</span></a></li></ul></li><li class="stacked-nav__list-item" data-tracking="Supporting evidence"><a aria-current="false" href="../../supporting-evidence/index.html"><span class="stacked-nav__content-wrapper">Supporting evidence</span></a></li><li class="stacked-nav__list-item" data-tracking="How this topic was developed"><a aria-current="false" href="../../how-this-topic-was-developed/index.html"><span class="stacked-nav__content-wrapper">How this topic was developed</span></a></li><li class="stacked-nav__list-item" data-tracking="References"><a aria-current="false" href="../../references/index.html"><span class="stacked-nav__content-wrapper">References</span></a></li></ul></nav></div><div class="ChapterContents-module--onThisPage--1333P"><nav class="ChapterOnThisPage-module--wrapper--2zc7n" aria-labelledby="on-this-page"><h2 class="ChapterOnThisPage-module--heading--2SdDN" id="on-this-page">On this page</h2><ol class="ChapterOnThisPage-module--rootList--2II70" aria-label="Jump links to section on this page"><li><a href="index.html#initial-assessment">Initial assessment</a><ol aria-label="Sections within Initial assessment" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#fraser-criteria">Fraser criteria</a></li><li class=""><a href="index.html#indications">Indications</a></li><li class=""><a href="index.html#liver-enzyme-inducing-drugs">Liver enzyme-inducing drugs</a></li><li class=""><a href="index.html#contraindications-restrictions">Contraindications/restrictions</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-643">Basis for recommendation</a></li></ol></li><li><a href="index.html#choice-of-emergency-contraception">Choice of emergency contraception</a><ol aria-label="Sections within Choice of emergency contraception" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#within-120-hours-since-last-upsi">Within 120 hours since last UPSI</a></li><li class=""><a href="index.html#120-hours-or-more-since-last-upsi-or-time-unknown">120 hours or more since last UPSI (or time unknown)</a></li><li class=""><a href="index.html#women-taking-certain-medications">Women taking certain medications</a></li><li class=""><a href="index.html#postpartum-or-breastfeeding-women">Postpartum or breastfeeding women</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-428">Basis for recommendation</a></li></ol></li><li><a href="index.html#risks-adverse-effects">Risks and adverse effects</a><ol aria-label="Sections within Risks and adverse effects" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#copper-intrauterine-device">Copper intrauterine device</a></li><li class=""><a href="index.html#ulipristal-acetate">Ulipristal acetate</a></li><li class=""><a href="index.html#levonorgestrel">Levonorgestrel</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-4ff">Basis for recommendation</a></li></ol></li><li><a href="index.html#information-advice-for-the-women">Information and advice for the women</a><ol aria-label="Sections within Information and advice for the women" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#copper-intrauterine-device">Copper intrauterine device</a></li><li class=""><a href="index.html#ulipristal-acetate">Ulipristal acetate</a></li><li class=""><a href="index.html#levonorgestrel">Levonorgestrel</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-8a8">Basis for recommendation</a></li></ol></li><li><a href="index.html#continuing-or-starting-regular-contraception">Continuing or starting regular contraception</a><ol aria-label="Sections within Continuing or starting regular contraception" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#after-ulipristal-acetate">After ulipristal acetate</a></li><li class=""><a href="index.html#after-levonorgestrel">After levonorgestrel</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-be0">Basis for recommendation</a></li></ol></li><li><a href="index.html#additional-or-advance-provision-of-emergency-contraception">Additional or advance provision of emergency contraception</a><ol aria-label="Sections within Additional or advance provision of emergency contraception" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-bac">Basis for recommendation</a></li></ol></li></ol></nav></div><div class="ChapterContents-module--body--1XBoo"><section aria-labelledby="management" class="ChapterBody-module--wrapper--2HCfk "><h2 id="management" class="visually-hidden">Scenario: Emergency hormonal contraception</h2><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 4e5639c1-a665-445f-86ba-bc9123d334b5 --><!-- begin field a595aabd-fae5-4e83-a165-acd900abd9b9 --><p>From age 13 years to 60 years (Female).</p><!-- end field a595aabd-fae5-4e83-a165-acd900abd9b9 --><!-- end item 4e5639c1-a665-445f-86ba-bc9123d334b5 --></div><section aria-labelledby="initial-assessment" class="ChapterBody-module--wrapper--2HCfk "><h3 id="initial-assessment">How should I assess a woman requesting emergency contraception?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ba5bd9d8-c076-4efd-82cd-731b3a8a41e7 --><!-- begin field 0205ad39-91e9-4bb0-bdc3-acc001006538 --><p><strong>When a woman requests emergency contraception (EC):</strong></p><ul><li><strong>Reassure her that the consultation will remain confidential, </strong>but explain the circumstances in which confidentiality may need to be breached (for example, suspected child protection issues). </li><li><strong>If a girl younger than 16 years of age requests EC <em>without </em>parental consent,</strong> assess her competency to independently consent to treatment, and document in her case notes that she meets (or does not meet) the <a class="topic-reference internal-reference" href="index.html#fraser-criteria">Fraser criteria</a>.</li><li><strong>Assess whether EC is indicated. </strong><ul><li>Consider EC if a woman does not wish to conceive and has had unprotected sexual intercourse (UPSI):<ul><li>On any day of a natural menstrual cycle. </li><li>After regular hormonal contraception has been <a class="topic-reference internal-reference" href="index.html#indications">compromised or used incorrectly</a>. </li><li>From day 21 after childbirth, unless all the lactational amenorrhea method (LAM) criteria are met (complete amenorrhea, fully or nearly fully breastfeeding [that is, baby getting more than 85% of its feeds as breast milk], and 6 months or less postpartum).</li><li>From day 5 after miscarriage, abortion, ectopic pregnancy, or uterine evacuation for gestational trophoblastic disease (GTD). </li></ul></li></ul></li><li><strong>Take a full history to help decide on the most appropriate method of EC.  </strong><ul><li>Ask when the most recent UPSI occurred and whether additional UPSI has occurred in the same cycle.<br><ul><li>Consider arranging a pregnancy test if the woman has had UPSI earlier in the cycle. Be aware that pregnancy testing cannot reliably exclude pregnancy if there has been an episode of UPSI less than 21 days previously.</li></ul></li><li>Discuss her menstrual history:<ul><li>Ask about the date of the start of her last menstrual period (LMP) and the usual cycle length.</li><li>Calculate the earliest likely date of ovulation (estimated as the date of the start of her LMP <em>plus</em> the number of days in the shortest cycle <em>minus</em> 14).</li></ul></li><li>Ask about previous use of hormonal EC (confirm which was taken and when it was taken).</li><li>Ask about other factors that could affect the choice of EC, including:<ul><li>Whether she is postpartum or breastfeeding.</li><li>Current medications (with particular attention to <a class="topic-reference internal-reference" href="index.html#liver-enzyme-inducing-drugs">liver enzyme-inducing drugs</a> and progestogens).</li><li>Contraindications/restrictions. The <a class="topic-reference internal-reference" href="index.html#contraindications-restrictions">UK Medical Eligibility Criteria for Contraceptive Use (UKMEC)</a> offers guidance on the safety of different contraceptives in women with particular medical conditions or personal characteristics.</li></ul></li></ul></li><li><strong>Carry out a risk assessment for sexual abuse, rape, and non-consensual sex,</strong> particularly if the woman is considered to be vulnerable (that is, younger than 16 years of age; is from a disadvantaged background; is in, or is leaving, care; has low educational attainment).<ul><li>The legal age of consent to sexual activity is 16 years in the UK.<ul><li>Sexual activity under the age of consent is an offence, even if consensual.</li><li>Offences are considered more serious (statutory rape) when the person is younger than 13 years of age.</li></ul></li><li>If non-consensual sex or sexual abuse is suspected, see the CKS topics on <a class="topic-reference external-reference" href="../../../domestic-violence-abuse/index.html">Domestic violence and abuse</a> and <a class="topic-reference external-reference" href="../../../child-maltreatment-recognition-management/index.html">Child maltreatment - recognition and management</a> for more information.</li></ul></li><li><strong> </strong><strong>C</strong><strong>onsider the risk of sexually transmitted infections (STIs).</strong><ul><li>Offer the woman the opportunity to test for STIs, including HIV. See the CKS topic on <a class="topic-reference external-reference" href="../../../hiv-infection-aids/index.html">HIV infection and AIDS</a> for more information.</li><li>Antibiotic cover may be considered before inserting the copper intrauterine device (Cu-IUD) if there is a significant risk of STI that could be associated with ascending pelvic infection. See the CKS topics on <a class="topic-reference external-reference" href="../../../chlamydia-uncomplicated-genital/index.html">Chlamydia - uncomplicated genital</a> and <a class="topic-reference external-reference" href="../../../contraception-ius-iud/index.html">Contraception - IUS/IUD</a> for more information.</li></ul></li><li><strong>Offer EC if indicated/appropriate.</strong><ul><li>See the section on <a class="topic-reference internal-reference" href="index.html#choice-of-emergency-contraception">Choice of emergency contraception</a> for more information.</li></ul></li><li><strong>Give advice on the need for ongoing contraception. </strong><ul><li>See the section on <a class="topic-reference internal-reference" href="index.html#continuing-or-starting-regular-contraception">Continuing or starting regular contraception</a> for more information.</li></ul></li><li><strong>If the woman is requesting additional or advance provision of oral EC:</strong><ul><li>See the section on <a class="topic-reference internal-reference" href="index.html#additional-or-advance-provision-of-emergency-contraception"> Additional or advance provision of emergency contraception</a> for more information.</li></ul></li></ul><!-- end field 0205ad39-91e9-4bb0-bdc3-acc001006538 --><!-- end item ba5bd9d8-c076-4efd-82cd-731b3a8a41e7 --></div><section aria-labelledby="fraser-criteria" class="ChapterBody-module--wrapper--2HCfk "><h4 id="fraser-criteria">Fraser criteria</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item a2772535-a251-45d5-ad80-62774f9495b4 --><!-- begin field 96c81def-3c38-4336-9eb4-acc001006538 --><ul><li><strong>In the UK, people 16 years of age and older are presumed to be competent to consent to medical treatment. In contrast, competence to consent to medical treatment must be demonstrated in children younger than 16 years of age.</strong><ul><li>In England and Wales, it is lawful to provide contraceptive advice and treatment to young people without parental consent, provided that the practitioner is satisfied that the Fraser criteria for competence are met. The criteria are that:<ul><li>The young person understands the practitioner's advice.</li><li>The young person cannot be persuaded to inform their parents, or will not allow the practitioner to inform the parents, that contraceptive advice has been sought.</li><li>The young person is likely to begin or to continue having intercourse with or without contraceptive treatment.</li><li>Unless he or she receives contraceptive advice or treatment, the young person's physical or mental health (or both) are likely to suffer.</li><li>The young person's best interest requires the practitioner to give contraceptive advice or treatment (or both) without parental consent.</li></ul></li><li>In Scotland, the Fraser guidelines do not apply; however, the Age of Legal Capacity Act 1991 applies similar criteria. Competence is demonstrated if the young person is able to:<ul><li>Understand the treatment, its purpose and nature, and why it is being proposed.</li><li>Understand its benefits, risks, and alternatives.</li><li>Understand in broader terms what the consequences of the treatment will be.</li><li>Retain the information for long enough to use it and weigh it up in order to arrive at a decision.</li></ul></li></ul></li></ul><!-- end field 96c81def-3c38-4336-9eb4-acc001006538 --><!-- end item a2772535-a251-45d5-ad80-62774f9495b4 --></div></section><section aria-labelledby="indications" class="ChapterBody-module--wrapper--2HCfk "><h4 id="indications">Indications for emergency contraception following potential failure of regular contraception</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item b4ed57b7-8ff1-4184-905b-6733751c98f2 --><!-- begin field ad840867-0fa8-4ba7-a57d-acc00117a595 --><p><strong>Examples of indications for emergency contraception following potential failure of hormonal and intrauterine methods of contraception are as follows:</strong></p><ul><li><strong>Hormonal contraception methods </strong><ul><li><strong>Failure to use additional contraceptive precautions when starting the method:</strong><ul><li>Emergency contraception (EC) is indicated if there has been unprotected sexual intercourse (UPSI) or barrier failure during the time that additional precautions are required for that method of contraception. See the CKS topics on <a class="topic-reference external-reference" href="../../../contraception-combined-hormonal-methods/index.html">Contraception - combined hormonal methods</a>, <a class="topic-reference external-reference" href="../../../contraception-ius-iud/index.html">Contraception - IUS/IUD</a>, and <a class="topic-reference external-reference" href="../../../contraception-progestogen-only-methods/index.html">Contraception - progestogen-only methods</a> for more information.</li></ul></li></ul></li><li><strong>Combined hormonal contraception (CHC)</strong><ul style="font-weight: 400;"><li><strong><strong><strong>Failure to use additional contraceptive precautions whilst using liver enzyme-inducing drugs or in the 28 days after use:</strong></strong></strong><ul><li>EC is indicated if there has been UPSI or barrier failure during, or in the 28 days following, use of liver enzyme-inducing drugs.</li><li>Offer a copper intrauterine device (Cu-IUD), which is unaffected by liver enzyme-inducing drugs or a double dose (3 mg) of levonorgestrel.</li><li>Ulipristal acetate is not recommended in this situation.</li></ul></li></ul></li><li><strong>Combined hormonal transdermal patch or combined hormonal vaginal ring</strong><ul><li><strong>Patch detachment/ring removal for more than 48 hours, or extension of patch-free or ring-free interval by more than 48 hours:</strong><ul><li>EC is indicated if patch detachment occurs in week 1 and there has been UPSI or barrier failure during the hormone-free interval (HFI) or week 1.</li><li>If the HFI is extended, a Cu-IUD can be offered up to 13 days after the start of the HFI assuming previous perfect use.</li><li>If CHC has been used in the 7 days prior to EC, the effectiveness of ulipristal acetate could theoretically be reduced. Consider use of levonorgestrel.</li></ul></li></ul></li><li><strong>Combined oral contraceptive (COC) pill (monophasic pill containing ethinylestradiol)</strong><ul><li><strong>Missed pills (if two or more active pills are missed):</strong><ul><li>EC is indicated if the pills are missed in week 1 and there has been UPSI or barrier failure during the pill-free interval or in week 1.</li><li>If the pill-free interval is extended (this includes missing pills in week 1), a Cu-IUD can be offered up to 13 days after the start of the HFI assuming previous perfect use.</li><li>If COC has been used in the 7 days prior to EC, the effectiveness of ulipristal acetate could theoretically be reduced. Consider use of levonorgestrel.</li></ul></li></ul></li><li><strong>Progestogen-only pill (POP)</strong><ul><li><strong>Failure to use additional contraceptive precautions whilst using liver enzyme-inducing drugs or in the 28 days after use:</strong><ul><li>EC is indicated if there has been UPSI or barrier failure during, or in the 28 days following, use of liver enzyme-inducing drugs.</li><li>Offer a Cu-IUD, which is unaffected by liver enzyme-inducing drugs or a double dose (3 mg) of levonorgestrel.</li><li>Ulipristal acetate is not recommended in this situation.</li></ul></li><li><strong>Late or missed pill (more than 27 hours since last traditional POP or more than 36 hours since last desogestrel-only pill):</strong><ul><li>EC is indicated if a pill is late or missed and there has been UPSI or barrier failure before efficacy has been re-established (that is, 48 hours after restarting).</li><li>The timing of ovulation after missed pills cannot be accurately predicted. A Cu-IUD is therefore only recommended up to 5 days after the first UPSI following a missed POP.</li><li>If POP has been taken in the 7 days prior to EC, the effectiveness of ulipristal acetate could theoretically be reduced. Consider using levonorgestrel.</li></ul></li></ul></li><li><strong>Progestogen-only injectable (</strong><strong>depot medroxyprogesterone acetate [DMPA])</strong><ul><li><strong>Late injection (more than 14 weeks since the last injection of DMPA):</strong><ul><li>EC is indicated if there has been UPSI or barrier failure more than 14 weeks after the last injection, and within the first 7 days after late injection.</li><li>The timing of ovulation after expiry of the progestogen-only injectable is extremely variable.</li><li>A Cu-IUD is only recommended up to 5 days after the first UPSI that takes place more than 14 weeks after the last DMPA injection.</li><li>The effectiveness of ulipristal acetate could theoretically be reduced by residual circulating progestogen. Consider using levonorgestrel.</li></ul></li></ul></li><li><strong>Progestogen-only implant (Nexplanon<sup>®</sup>) </strong><ul><li><strong>Failure to use additional contraceptive precautions whilst using liver enzyme-inducing drugs or in the 28 days after use:</strong><ul><li>EC is indicated if there has been UPSI or barrier failure during, or in the 28 days following, use of liver enzyme-inducing drugs.</li><li>Offer a copper intrauterine device (Cu-IUD), which is unaffected by liver enzyme-inducing drugs or a double dose (3 mg) of levonorgestrel.</li><li>Ulipristal acetate is not recommended in this situation.</li></ul></li><li><strong>Expired implant:</strong><ul><li>The risk of pregnancy in the fourth year of use of the progestogen-only implant is extremely low.</li><li>EC is unlikely to be required but may be considered.</li></ul></li></ul></li><li><strong>Copper intrauterine device (Cu-IUD)</strong><ul><li><strong>Removal without immediate replacement; partial or complete expulsion; threads missing and Cu-IUD location unknown:</strong><ul><li>EC is indicated if UPSI has taken place in the 7 days prior to removal, perforation, or partial or complete expulsion.</li><li>Oral EC is indicated if there has been UPSI in the last 5 days.</li><li>Depending on the timing of UPSI and time since IUD known to be correctly placed, it may be appropriate to fit another Cu-IUD for EC.</li></ul></li></ul></li><li><strong>Levonorgestrel-releasing intrauterine system (LNG-IUS)</strong><ul><li><strong>Removal without immediate replacement; partial or complete expulsion; threads missing and Cu-IUD location unknown:</strong><ul><li>EC is indicated if UPSI has taken place in the 7 days prior to removal, perforation, or partial or complete expulsion.</li><li>Oral EC is indicated if there has been UPSI in the last 5 days.</li><li>Depending on the timing of UPSI and time since IUD known to be correctly placed, it may be appropriate to fit another Cu-IUD for EC.</li></ul></li><li><strong>Expired IUS:</strong><ul><li>The risk of pregnancy in the sixth year of use of the LNG-IUS (Mirena<sup>®</sup>) is extremely low. EC is unlikely to be required but may be considered.</li></ul></li></ul></li></ul><!-- end field ad840867-0fa8-4ba7-a57d-acc00117a595 --><!-- end item b4ed57b7-8ff1-4184-905b-6733751c98f2 --></div></section><section aria-labelledby="liver-enzyme-inducing-drugs" class="ChapterBody-module--wrapper--2HCfk "><h4 id="liver-enzyme-inducing-drugs">Liver enzyme-inducing drugs</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item b8d2505a-5a44-44dd-8964-df0e7fa1a1a5 --><!-- begin field 363a33e5-bc12-45c2-a5d8-acc800eb27f6 --><ul><li><strong>Drugs that induce liver enzymes include:</strong><ul><li><strong><strong><strong>Antibiotics:</strong></strong></strong><ul style="font-weight: 400;"><li>Rifampicin (potent inducer).</li><li>Rifabutin.</li></ul></li><li><strong>Antiepileptics:</strong><ul><li>Carbamazepine.</li><li>Eslicarbazepine.</li><li>Oxcarbazepine.</li><li>Phenytoin.</li><li>Phenobarbital.</li><li>Primidone.</li><li>Rufinamide.</li><li>Topiramate (weak inducer).</li></ul></li><li><strong>Antiretrovirals:</strong><ul><li>Protease inhibitors: ritonavir, atazanavir, darunavir, fosamprenavir, lopinavir, nelfinavir, saquinavir, and tipranavir. </li><li>Non-nucleoside reverse transcriptase inhibitors: efavirenz, nevirapine.</li><li>Always use the <a style="background-color: #ffffff;" href="https://www.hiv-druginteractions.org/" data-hyperlink-id="7d802575-f5b8-4258-ad14-acbf017e05eb">HIV Drug Interaction Checker</a> to identify potential interactions.</li></ul></li><li><strong>Others:</strong><ul><li>Bosentan.</li><li>Modafinil.</li><li>Aprepitant.</li><li>St John's Wort.</li></ul></li></ul></li></ul><!-- end field 363a33e5-bc12-45c2-a5d8-acc800eb27f6 --><!-- end item b8d2505a-5a44-44dd-8964-df0e7fa1a1a5 --></div></section><section aria-labelledby="contraindications-restrictions" class="ChapterBody-module--wrapper--2HCfk "><h4 id="contraindications-restrictions">Contraindications/restrictions to the use of emergency contraception</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 7cd56f66-9fec-4552-9f53-593da77d34e7 --><!-- begin field bffcf434-897d-477b-8681-acc800eb27f6 --><ul><li><strong><strong>The</strong> <a style="font-weight: 400;" href="https://www.fsrh.org/standards-and-guidance/documents/ukmec-2016/" data-hyperlink-id="9540ddef-5c18-40a3-8940-acd300f4e227"><strong>UK Medical Eligibility Criteria for Contraceptive Use</strong></a><strong> (UKMEC)</strong> <strong><strong>offers guidance on the safety of different contraceptives in women with particular medical conditions or personal characteristics. </strong></strong></strong>When applied in a clinical setting:<ul><li style="box-sizing: inherit;"><strong>UKMEC Category 1 </strong>indicates that there is no restriction for use.</li><li style="box-sizing: inherit;"><strong>UKMEC Category 2</strong> indicates that the method can generally be used, but more careful follow up may be required. The advantages of using the method generally outweigh the theoretical or proven risks.</li><li><strong>UKMEC Category 3</strong> indicates that the method can be used; however, it may require expert clinical judgement and/or referral to a specialist contraception provider since use is not usually recommended unless other methods are not available or acceptable. The theoretical or proven risks usually outweigh the advantages of using the method.</li><li><strong>UKMEC Category 4</strong> indicates that use in that condition poses an unacceptable health risk, so the method should not be used. </li></ul></li></ul><h5>The copper intrauterine device (Cu-IUD) </h5><ul><li><strong><strong> <strong>The Cu-IUD is a safe option for many women. However:</strong></strong></strong><ul style="font-weight: 400;"><li><strong>It is contraindicated (UKMEC 4) in the following circumstances:</strong> <ul><li>Post-abortion and postpartum sepsis.</li><li>Unexplained vaginal bleeding (suspicious for serious condition) before evaluation (initiation only).</li><li>Gestational trophoblastic disease (GTD): persistently elevated human chorionic gonadotropin (hCG) levels or malignant disease.</li><li>Cervical cancer: awaiting treatment (initiation only).</li><li>Endometrial cancer (initiation only).</li><li>Current symptomatic chlamydial infection (initiation only).</li><li>Current purulent cervicitis or gonorrhoea (initiation only).</li><li>Pelvic tuberculosis (initiation only).</li><li>Current pelvic inflammatory disease (PID) (initiation only).</li></ul></li><li><strong> It should be used with caution and after consultation with an expert (UKMEC 3) in the following circumstances:</strong><br><ul><li>48 hours to less than 4 weeks postpartum.</li><li>Organ transplant: complicated: graft failure (acute or chronic), rejection, cardiac allograft vasculopathy (all initiation only).</li><li>Known long QT syndrome (initiation only).</li><li>GTD: decreasing hCG levels.</li><li>Cervical cancer: radical trachelectomy.</li><li>Uterine fibroid with distortion of the uterine cavity.</li><li>Distorted uterine cavity.</li><li>Current asymptomatic chlamydial infection (initiation only).</li><li>HIV infected: CD4 count less than 200 cells/mm<sup>3</sup> (initiation only).</li><li>Pelvic tuberculosis (continuation only).</li></ul></li></ul></li><li><strong>If a woman has known symptomatic <em>Chlamydia trachomatis</em> infection or current <em>Neisseria gonorrhoeae</em> infection, </strong>antibiotic treatment should be completed prior to insertion of a Cu-IUD. See the CKS topics on <a class="topic-reference external-reference" href="../../../chlamydia-uncomplicated-genital/index.html">Chlamydia - uncomplicated genital</a> and <a class="topic-reference external-reference" href="../../../gonorrhoea/index.html">Gonorrhoea</a> for more information.</li><li><strong>If a woman has asymptomatic <em>C. trachomatis</em> infection,</strong> insertion of a Cu-IUD for EC may be considered after discussion with the woman regarding risk and benefit. Treatment with appropriate antibiotics should be given at the time of insertion (or sooner if possible).</li></ul><h5>Ulipristal acetate</h5><ul><li><strong>UKMEC includes no contraindications to the use of ulipristal acetate</strong> — UKMEC 1 in most circumstances, and UKMEC 2 in:<ul><li>Current deep vein thrombosis and pulmonary embolism (on anticoagulants).</li><li>Current or past breast cancer.</li><li>Inflammatory bowel disease (including Crohn’s disease and ulcerative colitis).</li><li>Acute intermittent porphyria.</li></ul></li><li><strong>However, the manufacturer of ellaOne<sup>®</sup> advises against use in women with severe asthma controlled with oral steroids </strong>because of the antiglucocorticoid effect of ulipristal acetate.</li></ul><h5>Levonorgestrel </h5><ul><li><strong>UKMEC includes no contraindications to the use of l</strong><strong>evonorgestrel </strong>— UKMEC 1 in most circumstances, and UKMEC 2 in:<br><ul><li>Current deep vein thrombosis and pulmonary embolism (on anticoagulants).</li><li>Current or past breast cancer.</li><li>Inflammatory bowel disease (including Crohn’s disease and ulcerative colitis).</li><li>Acute intermittent porphyria.</li></ul></li><li><strong>The manufacturer of Levonelle<sup>®</sup> states that it is not recommended in women with severe hepatic dysfunction. </strong>However, the Faculty of Sexual and Reproductive Healthcare (FSRH) states that 'pregnancy poses a significant risk in women with severe hepatic impairment and expert opinion suggests that use of a single dose of LNG 1.5 mg is therefore acceptable'.</li></ul><!-- end field bffcf434-897d-477b-8681-acc800eb27f6 --><!-- end item 7cd56f66-9fec-4552-9f53-593da77d34e7 --></div></section><section aria-labelledby="basis-for-recommendation-643" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-643">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 643034f6-cf65-4453-a3d3-7f0e9f3cbc59 --><!-- begin field a3a6ed66-6bde-4317-970d-acc001006538 --><p>These recommendations are largely based on the Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <em>Emergency contraception (March 2017, amended December 2020)</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2020</a>]. Recommendations are also based on the FSRH <em>UK Medical Eligibility Criteria Contraceptive Use: UKMEC 2016 (Amended September 2019)</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2019a</a>], the FSRH guideline <em>Contraceptive choices for young people (March 2010, amended May 2019)</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2019b</a>], and the Summaries of Product Characteristics (SPCs) for ellaOne<sup>®</sup> 30 mg tablet [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2017</a>] and Levonelle One Step<sup>®</sup> 1500 microgram tablet [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020</a>].</p><!-- end field a3a6ed66-6bde-4317-970d-acc001006538 --><!-- end item 643034f6-cf65-4453-a3d3-7f0e9f3cbc59 --></div></section></section><section aria-labelledby="choice-of-emergency-contraception" class="ChapterBody-module--wrapper--2HCfk "><h3 id="choice-of-emergency-contraception">Which emergency contraception should I offer?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 7d532a7a-4452-4cba-aa52-ab4d583d1053 --><!-- begin field 456761bd-b5b7-4524-bcbb-acbf011925c0 --><ul><li><strong>Three methods of emergency contraception (EC) are currently available in the UK:</strong> <ul><li><strong>The copper intrauterine device (Cu-IUD)</strong> — can be inserted for EC within 5 days (120 hours) after the first unprotected sexual intercourse (UPSI) in a cycle or within 5 days of the earliest estimated date of ovulation, whichever is later.</li><li><strong>Oral ulipristal acetate 30 mg tablet </strong>— licensed to be used within 5 days (120 hours) after UPSI or contraceptive failure.</li><li><strong>Oral levonorgestrel 1.5 mg tablet</strong> — licensed to be used within 72 hours after UPSI or contraceptive failure. It can also be used between 72–96 hours after UPSI or contraceptive failure (off-label use), but efficacy decreases with time.</li></ul></li><li><strong>The Cu-IUD is the most effective method of EC and should be offered to all women </strong><strong>provided the criteria for insertion are met and the method is acceptable to the woman.</strong><br><ul><li>Adolescents who need EC should be offered all methods of EC, including the Cu-IUD.</li><li>Women requiring EC after sexual assault should be offered all methods of EC, including the Cu-IUD.</li><li><strong>If criteria for insertion of a Cu-IUD are not met or a Cu-IUD is not acceptable to the woman,</strong> oral EC should be considered. </li></ul></li><li><strong><strong>Following the <a class="topic-reference internal-reference" href="index.html#initial-assessment">initial assessment</a>, the </strong>choice of EC should be made</strong> <strong>with the woman, taking additional factors into consideration,</strong> such as:<ul><li style="list-style-type: none;"><ul><li>Time since UPSI — <a class="topic-reference internal-reference" href="index.html#within-120-hours-since-last-upsi">within 120 hours since UPSI</a> or <a class="topic-reference internal-reference" href="index.html#120-hours-or-more-since-last-upsi-or-time-unknown">120 hours or more since UPSI (or time is unknown)</a>.</li><li><a class="topic-reference internal-reference" href="index.html#women-taking-certain-medications">Current medications</a> that may interact with oral EC (such as a liver enzyme-inducing drug).</li><li>Whether the woman is <a class="topic-reference internal-reference" href="index.html#postpartum-or-breastfeeding-women">postpartum or breastfeeding</a>.</li><li>The woman's <a class="topic-reference internal-reference" href="index.html#within-120-hours-since-last-upsi">body mass index/weight</a>.</li><li><a class="topic-reference internal-reference" href="index.html#contraindications-restrictions">Contraindications/restrictions</a> to the use of the different methods of EC.</li></ul></li></ul></li><li><strong>The woman should be given appropriate <a class="topic-reference internal-reference" href="index.html#information-advice-for-the-women">information and advice</a> on the different methods of EC to help her make an informed choice.</strong><ul><li>If all EC methods cannot be offered, she should be signposted to services that can provide them.</li></ul></li></ul><!-- end field 456761bd-b5b7-4524-bcbb-acbf011925c0 --><!-- end item 7d532a7a-4452-4cba-aa52-ab4d583d1053 --></div><section aria-labelledby="within-120-hours-since-last-upsi" class="ChapterBody-module--wrapper--2HCfk "><h4 id="within-120-hours-since-last-upsi">Which emergency contraception should I offer if it is currently within 120 hours since unprotected sexual intercourse?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 9f49564a-794a-4f54-bafa-de23647c3cb9 --><!-- begin field 5e34129c-f43f-45e6-bbd2-acd30020b449 --><ul><li><strong>If it is currently within</strong><strong> 120 hours since the last episode of </strong><strong>unprotected sexual intercourse (UPSI), </strong>ask whether additional UPSI has occurred in the same cycle (more than 120 hours ago):<br><ul><li><strong><strong><strong>If additional UPSI has <em>not </em>occurred in the same cycle:</strong></strong></strong><ul style="font-weight: 400;"><li>Offer the copper intrauterine device (Cu-IUD). </li><li>If the Cu-IUD is <a class="topic-reference internal-reference" href="index.html#contraindications-restrictions">contraindicated</a> or not acceptable to the woman, offer oral emergency contraception (EC) and suitable ongoing contraception.</li><li>If the woman needs to be referred on for the Cu-IUD to be fitted, offer oral EC at the time of referral in case the Cu-IUD cannot be inserted or the woman changes her mind. </li></ul></li><li><strong>If additional UPSI has occurred <strong>in the same cycle </strong>or the woman is unsure <em>and </em>it is currently 5 days or less after the earliest likely date of ovulation </strong>(estimated as the date of the start of the last menstrual period [LMP] <em>plus</em> the number of days in the shortest cycle <em>minus</em> 14):<ul><li>Offer the Cu-IUD. </li><li>If the Cu-IUD is <a class="topic-reference internal-reference" href="index.html#contraindications-restrictions">contraindicated</a> or not acceptable to the woman, offer oral EC and suitable ongoing contraception.</li><li>If the woman needs to be referred on for the Cu-IUD to be fitted, offer oral EC at the time of referral in case the Cu-IUD cannot be inserted or the woman changes her mind. </li></ul></li><li><strong>If additional UPSI has occurred in the same cycle <strong>or the woman is unsure</strong> <em>and</em> it is currently more than 5 days after <strong>the earliest likely date of ovulation or </strong>the woman is unsure:</strong><br><ul><li>Offer oral EC and suitable ongoing contraception.</li><li>Consider pregnancy testing if the earlier UPSI occurred more than 21 days ago and the woman has not had a normal menstrual period since then (that is, UPSI occurred in the same cycle). </li></ul></li></ul></li></ul><h5>Choice of oral EC </h5><ul><li><strong>If the last UPSI occurred between 96–120 hours ago or the woman is unsure:</strong><br><ul><li>Offer ulipristal acetate plus regular contraception (to be started after 5 days of taking ulipristal acetate). </li><li>Levonorgestrel is unlikely to be effective.</li><li>Reconsider the Cu-IUD if all UPSI occurred within 120 hours, or if it is currently within 5 days after the likely date of ovulation.</li></ul></li><li><strong>If the last episode of UPSI occurred less than 96 hours ago, </strong>work out the earliest likely date of ovulation<strong> </strong>(estimated as the date of the start of the LMP <em>plus</em> the number of days in the shortest cycle <em>minus</em> 14):<ul><li><strong>If UPSI is likely to have taken place during the 5 days before the earliest likely date of ovulation or the woman is unsure:</strong><br><ul><li>Offer ulipristal acetate plus regular contraception (to be started after 5 days of taking ulipristal acetate).</li><li>If ulipristal acetate is not suitable, offer levonorgestrel plus immediate quick start of suitable hormonal contraception.</li><li>Reconsider the Cu-IUD if UPSI is within 120 hours, or if it is currently within 5 days after likely ovulation.</li></ul></li><li><strong>If UPSI is unlikely to have taken place during the 5 days before the earliest likely date of ovulation, </strong>consider the woman's weight and body mass index (BMI):<br><ul><li><strong>If the woman's BMI is less than 26 kg/m<sup>2</sup> or body weight is less than 70 kg,</strong> offer levonorgestrel plus immediate quick start of suitable hormonal contraception, or ulipristal acetate plus regular contraception (to be started after 5 days of taking ulipristal acetate).</li><li><strong>If the woman's BMI is more than 26 kg/m<sup>2</sup> or body weight is more than 70 kg,</strong> offer ulipristal acetate plus regular contraception (to be started after 5 days of taking ulipristal acetate), or double dose (3 mg) levonorgestrel plus immediate quick start of suitable hormonal contraception.</li></ul></li></ul></li><li><strong>Note that:</strong><ul><li>There is no evidence that oral EC is effective if ovulation has already occurred.</li><li>Ulipristal acetate is not suitable for use by women who have severe asthma controlled by oral glucocorticoids.</li></ul></li></ul><!-- end field 5e34129c-f43f-45e6-bbd2-acd30020b449 --><!-- end item 9f49564a-794a-4f54-bafa-de23647c3cb9 --></div></section><section aria-labelledby="120-hours-or-more-since-last-upsi-or-time-unknown" class="ChapterBody-module--wrapper--2HCfk "><h4 id="120-hours-or-more-since-last-upsi-or-time-unknown">Which emergency contraception should I offer if it has been 120 hours or more since unprotected sexual intercourse (or the time is unknown)?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 34a0e27f-56ae-47d9-a1e5-c71784345203 --><!-- begin field e996f267-bc15-42bd-bee7-acd30024b38c --><ul><li><strong>If it is currently</strong> <strong>120 hours or more since last unprotected sexual intercourse (</strong><strong>UPSI), </strong>work out the earliest likely date of ovulation (estimated as the date of the start of the last menstrual period [LMP] <em>plus</em> the number of days in the shortest cycle <em>minus</em> 14):<ul><li><strong>If it is currently 5 days or less </strong><strong>after the earliest likely date of ovulation:</strong><br><ul><li>Offer the copper intrauterine device (Cu-IUD) and suitable quick start contraception. </li><li>Oral emergency contraception (EC) is unlikely to be effective.</li></ul></li><li><strong>If it is currently more than 5 days after <strong>the earliest likely date of ovulation or </strong>the woman is unsure:</strong><ul><li>Offer suitable quick start contraception. </li><li>Oral EC is unlikely to be effective.</li></ul></li></ul></li><li><strong>If the woman is unsure how long it has been since UPSI, </strong>work out the earliest likely date of ovulation (estimated as the date of the start of the LMP <em>plus</em> the number of days in the shortest cycle <em>minus</em> 14):<ul><li><strong><strong>If it is currently 5 days or less </strong><strong>after the </strong></strong><strong>earliest likely date of ovulation:</strong><ul><li>Offer the Cu-IUD. </li><li>If the Cu-IUD is <a class="topic-reference internal-reference" href="index.html#contraindications-restrictions">contraindicated</a> or not acceptable to the woman, offer oral EC and suitable ongoing contraception. Note that oral EC is unlikely to be effective if taken after ovulation.</li><li>If the woman needs to be referred on for the Cu-IUD to be fitted, offer oral EC at the time of referral in case the Cu-IUD cannot be inserted or the woman changes her mind. </li></ul></li><li><strong>If it is currently more than 5 days <strong><strong>after the </strong></strong><strong>earliest likely date of ovulation or</strong> the woman is unsure:</strong><ul><li>Offer oral EC and suitable ongoing contraception. Note that oral EC is unlikely to be effective if taken after ovulation.</li></ul></li></ul></li></ul><h5>Choice of oral EC </h5><ul><li><strong>If it is currently 120 hours or more since the last UPSI:</strong><ul><li>Oral EC is unlikely to be effective.</li><li>Consider immediate quick start of suitable hormonal contraception only.</li><li>Reconsider the Cu-IUD if it is currently within 5 days after likely ovulation.</li></ul></li></ul><!-- end field e996f267-bc15-42bd-bee7-acd30024b38c --><!-- end item 34a0e27f-56ae-47d9-a1e5-c71784345203 --></div></section><section aria-labelledby="women-taking-certain-medications" class="ChapterBody-module--wrapper--2HCfk "><h4 id="women-taking-certain-medications">Which emergency contraception should I offer to women taking certain medications?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 3384819f-d211-447f-88cd-17dd8fff62ac --><!-- begin field 664cb332-2845-4648-93e1-acd30020b449 --><ul><li><strong><strong>If the woman is </strong>taking liver enzyme-inducing drugs or is within 28 days of stopping a <a class="topic-reference internal-reference" href="index.html#liver-enzyme-inducing-drugs">liver enzyme-inducing drug</a> (such as rifampicin and carbamazepine):</strong><br><ul><li>The copper intrauterine device (Cu-IUD) is the preferred option.</li><li>If the Cu-IUD is <a class="topic-reference internal-reference" href="index.html#contraindications-restrictions">contraindicated</a> or not acceptable to the woman, offer double dose (3 mg) levonorgestrel to be taken as a single dose as soon as possible and within 72 hours of unprotected sexual intercourse (UPSI). Explain to the woman that this recommendation is outside the product licence and is based on expert clinical judgement.</li><li>Ulipristal acetate is not recommended.</li></ul></li><li><strong>If the woman has recently taken a product containing</strong> <strong>progestogen or progesterone</strong> (whether for contraceptive purposes, EC, gynaecological indications, or hormone replacement therapy [HRT]):<br><ul><li>Be aware that the effectiveness of ulipristal acetate:<ul><li>Could be reduced if the progestogen was taken in the 5 days after taking ulipristal acetate.</li><li>Could theoretically be reduced if the progestogen was taken in the 7 days prior to taking ulipristal acetate.</li></ul></li><li>It is unknown whether ulipristal acetate taken when there may still be circulating progestogen is more or less effective than levonorgestrel.</li></ul></li></ul><!-- end field 664cb332-2845-4648-93e1-acd30020b449 --><!-- end item 3384819f-d211-447f-88cd-17dd8fff62ac --></div></section><section aria-labelledby="postpartum-or-breastfeeding-women" class="ChapterBody-module--wrapper--2HCfk "><h4 id="postpartum-or-breastfeeding-women">Which emergency contraception should I offer to postpartum and breastfeeding women?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item e3a8d04f-719b-4cc8-a899-fee6f52b8ab4 --><!-- begin field 43529da4-9cde-43ad-8685-acd30020b449 --><ul><li><strong>In postpartum and breastfeeding women:</strong><ul><li>The copper intrauterine device (Cu-IUD) is suitable from 4 weeks or more postpartum.</li><li>If the Cu-IUD is <a class="topic-reference internal-reference" href="index.html#contraindications-restrictions">contraindicated</a> or not acceptable to the woman, consider oral emergency contraception (EC). The choice of EC will depend on factors such as:<ul><li>Time since unprotected sexual intercourse (UPSI) — <a class="topic-reference internal-reference" href="index.html#within-120-hours-since-last-upsi">within 120 hours since UPSI</a> or <a class="topic-reference internal-reference" href="index.html#120-hours-or-more-since-last-upsi-or-time-unknown">120 hours or more since UPSI (or time is unknown)</a>.</li><li><a class="topic-reference internal-reference" href="index.html#women-taking-certain-medications">Current medications</a> that may interact with oral EC (such as a liver enzyme-inducing drug).</li><li>The woman's <a class="topic-reference internal-reference" href="index.html#within-120-hours-since-last-upsi">body mass index/weight</a>.</li><li><a class="topic-reference internal-reference" href="index.html#contraindications-restrictions">Contraindications/restrictions</a>— ulipristal acetate is not suitable for use by women who have severe asthma controlled by oral glucocorticoids.</li></ul></li></ul></li><li><strong>In breastfeeding women:</strong><ul><li><strong>If levonorgestrel is prescribed, </strong>advise the woman that a small amount is excreted into breast milk. To minimize exposure to the infant, she should take levonorgestrel immediately after breastfeeding and avoid nursing for at least 8 hours following.</li><li><strong>If ulipristal acetate is prescribed,</strong> advise the woman not to breastfeed and to express and discard milk for a week after she has taken ulipristal acetate.</li></ul></li></ul><!-- end field 43529da4-9cde-43ad-8685-acd30020b449 --><!-- end item e3a8d04f-719b-4cc8-a899-fee6f52b8ab4 --></div></section><section aria-labelledby="basis-for-recommendation-428" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-428">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 42891fab-81d2-4031-9727-10630b648c95 --><!-- begin field 6069d816-c8b1-4341-92fa-acbf011925c0 --><p>These recommendations are largely based on the Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <em>Emergency contraception (March 2017, amended December 2020)</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2020</a>].</p><h5>Risk of pregnancy</h5><ul><li>Expert opinion in the FSRH guideline is that [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2020</a>]:<ul><li>Pregnancy is extremely unlikely to occur as a result of unprotected sexual intercourse (UPSI) in the first 3 days of a natural menstrual cycle. However, it is theoretically possible after UPSI on most days of the cycle.</li><li>A woman’s fertile period is considered to be the 6 consecutive days ending with (and including) the day of ovulation. In the days immediately prior to ovulation and on the day of ovulation itself, pregnancy risk following a single episode of UPSI has been estimated to be up to 30%. If a woman has one episode of UPSI in a cycle, there is a 25% chance that the UPSI takes place during her fertile period.</li><li>Because it can be difficult to predict whether an episode of UPSI has occurred during a woman’s fertile period, emergency contraception (EC) should be offered after UPSI on any day of a woman’s natural menstrual cycle. The choice of EC method may depend on whether it is considered likely that UPSI may have taken place during the woman’s fertile period.</li></ul></li></ul><h5>When to insert a copper intrauterine device (Cu-IUD)</h5><ul><li>This information is based on the FSRH guidelines on <em>Intrauterine contraception</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2019c</a>] and <em>Emergency contraception</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2020</a>].<ul><li>The Cu-IUD can be inserted within 5 days (120 hours) after the first unprotected sexual intercourse (UPSI) in a cycle [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2019c</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2020</a>].</li><li>The earliest implantation is believed to occur 6 days after ovulation (and over 80% of implantations occur 8–10 days after ovulation). Therefore, a Cu-IUD can also be inserted up to 5 days after ovulation (for example, until day 19 of a regular, 28-day cycle) [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2020</a>].<ul><li>Ovulation occurs about 14 days before the onset of menstruation.</li><li>It is established practice that the earliest likely ovulation date is estimated as the date of the start of the last menstrual period (LMP) plus the number of days in the shortest cycle minus 14.</li><li>The LMP must be accurately known and cycles must be regular in order to make the estimation [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2020</a>].</li></ul></li></ul></li></ul><h5>Use of liver enzyme-inducing drugs</h5><ul><li>The metabolism of both ulipristal acetate and levonorgestrel is increased during, and for 28 days after, use of drugs that induce liver enzymes [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2020</a>].</li><li>The FSRH advises that although the clinical relevance of this interaction in terms of potential reduction in effectiveness is unknown, a Cu-IUD should be recommended for women using enzyme-inducing drugs if the criteria for use are met, as the Cu-IUD is unaffected by liver enzyme induction. Alternatively, a single dose of 3 mg levonorgestrel (double the licensed dose) can be used off-label as recommended by the British National Formulary (BNF) and the Medicines and Healthcare products Regulatory Agency (MHRA).</li><li>The FSRH highlights that the effectiveness of 3 mg levonorgestrel for emergency contraception in this situation has not been studied and that the use of a double dose of ulipristal acetate is not recommended.</li></ul><h5>Use of progestogens</h5><ul><li>See the section on <a class="topic-reference internal-reference" href="index.html#basis-for-recommendation-be0">Continuing or starting contraception after&nbsp;ulipristal acetate</a> for more information.</li></ul><h5>Ulipristal acetate not suitable for use by women who have severe asthma controlled by oral glucocorticoids</h5><ul><li>The Summary of Product Characteristics (SPC) for ellaOne<sup>®</sup> advises against the use of ulipristal acetate in women with severe asthma controlled with oral steroids because of the antiglucocorticoid effect of ulipristal acetate [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2017</a>].</li></ul><!-- end field 6069d816-c8b1-4341-92fa-acbf011925c0 --><!-- end item 42891fab-81d2-4031-9727-10630b648c95 --></div></section></section><section aria-labelledby="risks-adverse-effects" class="ChapterBody-module--wrapper--2HCfk "><h3 id="risks-adverse-effects">What are the possible risks and adverse effects of the different types of emergency contraception?</h3><section aria-labelledby="copper-intrauterine-device" class="ChapterBody-module--wrapper--2HCfk "><h4 id="copper-intrauterine-device">What are the possible risks and adverse effects of the copper intrauterine device?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ad1f0c26-7422-46ac-892d-86b5bba96119 --><!-- begin field 25cfcb42-590d-4247-aaa4-acd700b0566c --><ul><li><strong>Possible risks and adverse effects of a copper intrauterine device (Cu-IUD) include:</strong><ul><li><strong>Pain on insertion</strong> — this may cause discomfort for a few hours but can be relieved with analgesics. </li><li><strong>Pelvic pain</strong> — pelvic pain or cramping has been reported by some women. </li><li><strong>Perforation of the wall of the uterus</strong> — this is rare (occurs in less than 2 in 1000 women) and is dependent on the skills of the clinician. There is an increased relative risk of perforation at the time of insertion of intrauterine contraception (IUC) in the postpartum period (within 36 weeks after giving birth) and during breastfeeding; however, the absolute risk of perforation remains low.</li><li><strong>Expulsion </strong>— the risk of expulsion is around 1 in 20 and is more common in the first year of use, especially within the first 3 months of insertion. There is a small increased risk of expulsion if the device is inserted immediately following surgical or medical termination of pregnancy.</li><li><strong>Pelvic inflammatory disease (PID)</strong> — there is a low risk of PID (1.6 per 1000 women-years), which is strongly related to the insertion procedure and background risk of sexually transmitted infections (STIs). The risk of pelvic infection is greatest in the first few weeks following IUC insertion.</li><li><strong>Ectopic pregnancy</strong> — the overall risk of ectopic pregnancy when using an IUC is very low, at about 1 in 1000 at 5 years. If pregnancy does occur with an intrauterine method in situ, the risk of an ectopic pregnancy occurring is increased; in some studies, half of the pregnancies that occurred were ectopic. The overall risk of ectopic pregnancy is reduced with the use of IUC when compared with using no contraception because IUCs are very effective methods of contraception overall.</li><li><strong>Unscheduled bleeding</strong> — irregular, prolonged, or frequent bleeding may occur in the 3–6 months following Cu-IUD insertion, but menstrual bleeding patterns tend to improve with time. </li><li><strong>Weight gain</strong> — this has been observed with the use of IUC, but evidence to support a causal association is lacking. </li><li><strong>Decreased libido</strong> — although existing evidence fails to support a negative effect on libido associated with IUC use. </li></ul></li></ul><!-- end field 25cfcb42-590d-4247-aaa4-acd700b0566c --><!-- end item ad1f0c26-7422-46ac-892d-86b5bba96119 --></div></section><section aria-labelledby="ulipristal-acetate" class="ChapterBody-module--wrapper--2HCfk "><h4 id="ulipristal-acetate">What are the possible risks and adverse effects of ulipristal acetate?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 1a3847d6-085d-4e93-9ed5-af0b35680a8c --><!-- begin field 886f2159-7daf-4e30-aa69-acd700b25076 --><ul><li><strong>Vomiting</strong> is common with ulipristal acetate.<ul><li>If the woman vomits up to 3 hours after taking ulipristal acetate, she should take a second dose as soon as possible.</li></ul></li><li><strong>Menstrual irregularities </strong>are also common.<br><ul><li>If the woman has early mild bleeding or spotting, this is probably caused by ulipristal acetate and may not be the start of the next menstrual cycle. She should not regard this time as safe for unprotected sexual intercourse. </li><li>Most women will have a normal period at the expected time; some women will have their period later or earlier than normal.</li><li>She should have a pregnancy test if her next period is more than 7 days late or bleeding is lighter than usual.</li></ul></li><li><strong>Ectopic pregnancy</strong> can occur if the woman becomes pregnant after ulipristal acetate; however, the risk is very small.<ul><li>The woman should seek prompt medical attention if she experiences severe lower abdominal pain after taking ulipristal acetate.</li><li>Ectopic pregnancy may continue despite the occurrence of uterine bleeding.</li><li>See the CKS topic on <a class="topic-reference external-reference" href="../../../ectopic-pregnancy/index.html">Ectopic pregnancy</a> for more information.</li></ul></li><li><strong>Other possible adverse effects of ulipristal acetate include:</strong><ul><li>Common — mood disorders, headache, dizziness, nausea, abdominal pain/discomfort, fatigue, back pain, pelvic pain, dysmenorrhoea, breast tenderness, and myalgia.</li><li>Uncommon — anxiety, appetite disorder, chills, concentration impaired, diarrhoea, drowsiness, dry mouth, fever, flatulence, hot flush, increased risk of infection, insomnia, libido disorder, malaise, skin reactions, vision disorders, and vulvovaginal disorders.</li><li>Rare or very rare — abnormal sensation in eye, disorientation, dry throat, eye erythema, genital pruritus, ovarian cyst rupture, painful sexual intercourse, syncope, taste altered, thirst, tremor, and vertigo.</li></ul></li></ul><!-- end field 886f2159-7daf-4e30-aa69-acd700b25076 --><!-- end item 1a3847d6-085d-4e93-9ed5-af0b35680a8c --></div></section><section aria-labelledby="levonorgestrel" class="ChapterBody-module--wrapper--2HCfk "><h4 id="levonorgestrel">What are the possible risks and adverse effects of levonorgestrel?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 36707a96-defc-4d4b-877c-f273a871f36e --><!-- begin field 410636df-071a-4800-9d55-acd700b25076 --><ul><li><strong>Vomiting</strong> is common with levonorgestrel.<ul><li>If the woman vomits up to 3 hours after taking levonorgestrel, she should take a second dose as soon as possible.</li></ul></li><li><strong>Menstrual irregularities </strong>are also common.<br><ul><li>If the woman has early mild bleeding or spotting, this is probably caused by levonorgestrel and may not be the start of the next menstrual cycle. She should not regard this time as safe for unprotected sexual intercourse. </li><li>Most women will have a normal period at the expected time; some women will have their period later or earlier than normal.</li><li>She should have a pregnancy test if her next period is more than 5–7 days late or bleeding is lighter than usual.</li></ul></li><li><strong>Ectopic pregnancy</strong> can occur if the woman becomes pregnant after levonorgestrel; however, the absolute risk is likely to be low.<ul><li>She should seek prompt medical attention if she experiences severe lower abdominal pain after taking levonorgestrel.</li><li>Ectopic pregnancy may continue despite the occurrence of uterine bleeding.</li><li>See the CKS topic on <a class="topic-reference external-reference" href="../../../ectopic-pregnancy/index.html">Ectopic pregnancy</a> for more information.</li></ul></li><li><strong>Other possible adverse effects of levonorgestrel include:</strong><ul><li>Headache.</li><li>Lower abdominal pain.</li><li>Fatigue.</li><li>Dizziness.</li><li>Diarrhoea.</li><li>Breast tenderness.</li></ul></li></ul><!-- end field 410636df-071a-4800-9d55-acd700b25076 --><!-- end item 36707a96-defc-4d4b-877c-f273a871f36e --></div></section><section aria-labelledby="basis-for-recommendation-4ff" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-4ff">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 4ff4dee4-f2d0-43f9-8542-fd25d4e4b2a7 --><!-- begin field 7321b334-62f2-4bf3-adca-acd700b0566c --><p>These recommendations are largely based on the Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <em>Emergency contraception (March 2017, amended December 2020)</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2020</a>], the Summaries of Product Characteristics (SPCs) for ellaOne<sup>®</sup> (ulipristal acetate) 30 mg tablet [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2017</a>] and Levonelle One Step<sup>®</sup> (levonorgestrel) 1500 microgram tablet [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020</a>], and the British National Formulary [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>].</p><!-- end field 7321b334-62f2-4bf3-adca-acd700b0566c --><!-- end item 4ff4dee4-f2d0-43f9-8542-fd25d4e4b2a7 --></div></section></section><section aria-labelledby="information-advice-for-the-women" class="ChapterBody-module--wrapper--2HCfk "><h3 id="information-advice-for-the-women">What information and advice should I give to a woman using emergency contraception?</h3><section aria-labelledby="copper-intrauterine-device" class="ChapterBody-module--wrapper--2HCfk "><h4 id="copper-intrauterine-device">What information and advice should I give to women using the copper intrauterine device?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 2c7d2fa1-4803-43b5-918c-82be6bd5467e --><!-- begin field cd7859c0-0b15-423a-b05f-acd200142d2c --><ul><li><strong>Discuss</strong> the <a class="topic-reference internal-reference" href="../../background-information/mode-of-action/index.html">mode of action</a>, <a class="topic-reference internal-reference" href="../../background-information/efficacy/index.html">efficacy</a>, <a class="topic-reference internal-reference" href="../../background-information/advantages-disadvantages/index.html#copper-intrauterine-device">advantages and disadvantages</a>, and possible <a class="topic-reference internal-reference" href="index.html#copper-intrauterine-device">risks and adverse effects</a> of the copper intrauterine device (Cu-IUD).</li><li><strong>Advise the woman:</strong><ul><li>On how to check for the Cu-IUD threads and the importance of doing this regularly (for example, after every menstrual period). </li><li>That the device can be removed at any time if she wishes to become pregnant and there is no delay in return to fertility.</li><li>That the Cu-IUD does not provide protection against sexually transmitted infections (STIs). Only a barrier method of contraception (such as a condom) can reduce the risk of STIs.</li></ul></li><li><strong>Advise the woman to seek medical advice if:</strong><br><ul><li>Menstrual abnormalities (such as unscheduled bleeding) persist beyond the initial 6 months of use.</li><li>She experiences possible features of pelvic inflammatory disease (pain or tenderness in the lower abdomen, fever, or abnormal or odorous vaginal discharge), especially within the first 3–4 weeks after insertion of the Cu-IUD. See the CKS topic on <a class="topic-reference external-reference" href="../../../pelvic-inflammatory-disease/index.html">Pelvic inflammatory disease</a> for management information.</li><li>She has mild lower abdominal pain and ‘lost threads’, especially with a history of pain at the time of insertion. These may indicate uterine perforation. </li><li>The device causes discomfort to her or her partner during sexual intercourse. (The threads can be cut shorter or flush within the cervical os if they cause irritation to a partner’s penis.)</li><li>She experiences any other <a class="topic-reference internal-reference" href="index.html#copper-intrauterine-device">adverse effect</a> of the Cu-IUD.</li></ul></li><li><strong>Provide information on:</strong><br><ul><li>The specific Cu-IUD that has been inserted and when it needs to be removed/replaced. See the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-ius-iud/index.html">Contraception - IUS/IUD</a> for more information.</li><li>Other sources of useful information and advice regarding the Cu-IUD. For example, the Family Planning Association provides a useful <a href="http://www.fpa.org.uk/sites/default/files/intrauterine-device-iud-your-guide.pdf" data-hyperlink-id="70d796c2-c331-46f1-8d08-a93100b62e78">leaflet</a> with information for users of the Cu-IUD.</li></ul></li></ul><!-- end field cd7859c0-0b15-423a-b05f-acd200142d2c --><!-- end item 2c7d2fa1-4803-43b5-918c-82be6bd5467e --></div></section><section aria-labelledby="ulipristal-acetate" class="ChapterBody-module--wrapper--2HCfk "><h4 id="ulipristal-acetate">What information and advice should I give to a woman taking ulipristal acetate emergency contraception?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 6a32dc0c-8da7-439b-bf48-d672cc8847e9 --><!-- begin field 1e0174e3-e09c-4222-adf6-acc001006538 --><ul><li><strong>Discuss (and provide information on)</strong> the <a class="topic-reference internal-reference" href="../../background-information/mode-of-action/index.html">mode of action</a>, <a class="topic-reference internal-reference" href="../../background-information/efficacy/index.html">efficacy</a>, <a class="topic-reference internal-reference" href="../../background-information/advantages-disadvantages/index.html#ulipristal-acetate">advantages and disadvantages</a>, and possible <a class="topic-reference internal-reference" href="index.html#ulipristal-acetate">risks and adverse effects</a> of ulipristal acetate.</li><li><strong>Advise the woman that:</strong><br><ul><li>She should take ulipristal acetate as soon as possible after unprotected sexual intercourse (UPSI), but within 120 hours.</li><li>If she vomits up to 3 hours after taking ulipristal acetate, she should take a second dose as soon as possible.</li><li>Her next menstrual period might be different:<ul><li>If she has early mild bleeding or spotting, this is probably caused by the ulipristal acetate and may not be the start of the next menstrual cycle. She should not regard this time as safe for UPSI. </li><li>Most women will have a normal period at the expected time; some women will have their period later or earlier than normal.</li></ul></li><li>Ulipristal acetate is not 100% effective. She should have a pregnancy test if her next period is more than 7 days late or bleeding is lighter than usual.</li><li>The <a class="topic-reference internal-reference" href="index.html#ulipristal-acetate">risk</a> of ectopic pregnancy is very small. However, she should seek prompt medical attention if she experiences severe lower abdominal pain after taking ulipristal acetate.</li><li>Ulipristal acetate does not protect against sexually transmitted infections (STIs). Only a barrier method of contraception (such as a condom) can reduce the risk of STIs.</li></ul></li><li><strong>If the woman is not currently using ongoing contraception:</strong><br><ul><li>Advise that she would need to use ongoing contraception or abstain from sex to avoid further risk of pregnancy. Ulipristal acetate:<ul><li>Is intended for occasional use and should in no instance replace a regular contraceptive method. </li><li>Does not provide contraceptive cover for the remainder of the cycle or for subsequent UPSI. There is a significantly increased risk of pregnancy with further UPSI later in the cycle in which oral emergency contraception has been taken.</li><li>Can be used more than once in the same cycle, but repeated administration is not advisable because of the possibility of disturbance of the cycle. See the section on <a class="topic-reference internal-reference" href="index.html#additional-or-advance-provision-of-emergency-contraception">Additional or advance provision of emergency contraception</a> for more information.</li></ul></li><li>Provide verbal and/or written information on all methods of ongoing contraception and information on how to access them.</li></ul></li><li><strong>If the woman is continuing or starting ongoing contraception:</strong><ul><li>See the section on <a class="topic-reference internal-reference" href="index.html#after-ulipristal-acetate">Continuing or starting contraception after&nbsp;ulipristal acetate</a> for more information.</li></ul></li><li><strong>If the woman becomes pregnant after taking ulipristal acetate:</strong><br><ul><li>Advise that evidence on the outcome of pregnancies exposed to ulipristal acetate is very limited. However, there have been no associated adverse outcomes with the small number of pregnancies that have been reported to date.</li><li>If she chooses to continue with her pregnancy, consider informing the manufacturers at <a href="http://www.hra-pregnancy-registry.com/en/" data-hyperlink-id="6a372ec1-8600-48c1-8f2f-acc8014c0054">www.hra-pregnancy-registry.com</a> (as they are maintaining an anonymized registry to monitor outcomes of pregnancy in women exposed to ulipristal acetate in utero) and reporting to the Medicines and Healthcare products Regulatory Agency (MHRA) via the Yellow Card Scheme.</li></ul></li></ul><!-- end field 1e0174e3-e09c-4222-adf6-acc001006538 --><!-- end item 6a32dc0c-8da7-439b-bf48-d672cc8847e9 --></div></section><section aria-labelledby="levonorgestrel" class="ChapterBody-module--wrapper--2HCfk "><h4 id="levonorgestrel">What information and advice should I give to a woman taking levonorgestrel emergency contraception?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 2dba0ca7-e077-42cf-8be0-58a3b806e3a7 --><!-- begin field 890b0221-8f1a-4b8f-8360-acbf01743a18 --><ul><li><strong>Discuss (and provide information on) </strong>the <a class="topic-reference internal-reference" href="../../background-information/mode-of-action/index.html">mode of action</a>, <a class="topic-reference internal-reference" href="../../background-information/efficacy/index.html">efficacy</a>, <a class="topic-reference internal-reference" href="../../background-information/advantages-disadvantages/index.html#levonorgestrel">advantages and disadvantages</a>, and possible <a class="topic-reference internal-reference" href="index.html#levonorgestrel">risks and adverse effects</a> of levonorgestrel.</li><li><strong>Advise the woman that:</strong><br><ul><li>She should take levonorgestrel as soon as possible after unprotected sexual intercourse (UPSI), but within 72 hours.</li><li>If she vomits up to 3 hours after taking levonorgestrel, she should take a second dose as soon as possible.</li><li>Her next menstrual period might be different:<ul><li>If she has early mild bleeding or spotting, this is probably caused by levonorgestrel and may not be the start of the next menstrual cycle. She should not regard this time as safe for UPSI. </li><li>Most women will have a normal period at the expected time; some women will have their period later or earlier than normal.</li></ul></li><li>Levonorgestrel is not 100% effective. She should have a pregnancy test if her next period is more than 5–7 days late or bleeding is lighter than usual.  </li><li>The <a class="topic-reference internal-reference" href="index.html#levonorgestrel">risk</a> of ectopic pregnancy is very small. However, she should seek prompt medical attention if she experiences severe lower abdominal pain after taking levonorgestrel.</li><li>Levonorgestrel does not protect against sexually transmitted infections (STIs). Only a barrier method of contraception (such as a condom) can reduce the risk of STIs.</li></ul></li><li><strong>If the woman is not currently using ongoing contraception:</strong> <br><ul><li>Advise that she would need to use ongoing contraception or abstain from sex to avoid further risk of pregnancy. Levonorgestrel:<ul><li>Is intended for occasional use and should in no instance replace a regular contraceptive method. </li><li>Does not provide contraceptive cover for the remainder of the cycle or for subsequent UPSI. There is a significantly increased risk of pregnancy with further UPSI later in the cycle in which oral emergency contraception has been taken.</li><li>Can be used more than once in the same cycle, but repeated administration is not advisable because of the possibility of disturbance of the cycle. See the section on <a class="topic-reference internal-reference" href="index.html#additional-or-advance-provision-of-emergency-contraception">Additional or advance provision of emergency contraception</a> for more information.</li></ul></li><li>Provide verbal and/or written information on all methods of ongoing contraception and information on how to access them.</li></ul></li><li><strong>If the woman is continuing or starting ongoing contraception:</strong><ul><li>See the section on <a class="topic-reference internal-reference" href="index.html#after-levonorgestrel">Continuing or starting contraception after&nbsp;levonorgestrel</a> for more information.</li></ul></li><li><strong>If the woman becomes pregnant after taking levonorgestrel:</strong><br><ul><li>Advise that levonorgestrel will not interrupt an existing pregnancy and limited epidemiological data indicate no adverse effects on the fetus. However, there are no clinical data on the potential consequences if doses greater than 1.5 mg of levonorgestrel are taken.</li></ul></li></ul><!-- end field 890b0221-8f1a-4b8f-8360-acbf01743a18 --><!-- end item 2dba0ca7-e077-42cf-8be0-58a3b806e3a7 --></div></section><section aria-labelledby="basis-for-recommendation-8a8" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-8a8">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 8a8cd2b3-40c1-41a6-9e27-4f5f81fc18ff --><!-- begin field e85f2edf-a713-48c7-907f-acbf01743a18 --><p>These recommendations are largely based on the Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <em>Emergency contraception (March 2017, amended December 2020)</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2020</a>] and the Summaries of Product Characteristics (SPCs) for ellaOne<sup>®</sup> (ulipristal acetate) 30 mg tablet [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2017</a>] and Levonelle One Step<sup>®</sup> (levonorgestrel) 1500 microgram tablet [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020</a>].</p><!-- end field e85f2edf-a713-48c7-907f-acbf01743a18 --><!-- end item 8a8cd2b3-40c1-41a6-9e27-4f5f81fc18ff --></div></section></section><section aria-labelledby="continuing-or-starting-regular-contraception" class="ChapterBody-module--wrapper--2HCfk "><h3 id="continuing-or-starting-regular-contraception">How should a woman continue or start regular contraception after emergency contraception?</h3><section aria-labelledby="after-ulipristal-acetate" class="ChapterBody-module--wrapper--2HCfk "><h4 id="after-ulipristal-acetate">How should a woman continue or start ongoing contraception after ulipristal acetate emergency contraception?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item a0b74429-eed9-4986-aa99-418669479243 --><!-- begin field 01015dc6-18d1-4f83-8733-acbf0138f777 --><ul><li><strong>If the woman is continuing or starting combined hormonal contraception (CHC [pill, patch, and vaginal ring]) after</strong> <strong>ulipristal acetate emergency contraception (EC):</strong><br><ul><li>Advise that:<ul><li>She should wait 5 days (at least 120 hours) after taking ulipristal acetate before continuing or starting CHC, with a pregnancy test 21 days later to exclude pregnancy resulting from EC failure.</li><li>She should use additional contraception (such as a condom) or avoid sexual intercourse until the CHC becomes effective. See the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-combined-hormonal-methods/index.html">Contraception - combined hormonal methods</a> for more information.</li></ul></li><li><strong>There is one specific exception to this:</strong><ul><li>If CHC pills are restarted after a scheduled hormone-free interval and pills are then missed later in the first week of pill taking, ulipristal acetate may be considered, with immediate restart of pill taking. If ulipristal acetate is used in this specific situation, pill-taking can be resumed immediately after taking the ulipristal acetate.</li></ul></li></ul></li><li><strong>If the woman is continuing or starting progestogen-only contraception (pill, implant, and injectable) after</strong> <strong><strong>ulipristal acetate</strong> EC:</strong><br><ul><li>Advise that:<ul><li>She should wait 5 days (at least 120 hours) after taking ulipristal acetate before continuing or starting the progestogen-only contraception, with a pregnancy test 21 days later to exclude pregnancy resulting from EC failure.</li><li>She should use additional contraception (such as a condom) or avoid sexual intercourse until the progestogen-only contraception becomes effective. See the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-progestogen-only-methods/index.html">Contraception - progestogen-only methods</a> for more information.</li></ul></li></ul></li><li><strong>If the woman is considering starting t</strong><strong>he copper intrauterine device (Cu-IUD) </strong><strong>after </strong><strong><strong>ulipristal acetate</strong> EC:</strong><br><ul><li>Insert the Cu-IUD within the first 5 days (120 hours) after the first episode of UPSI or within 5 days of the earliest expected time of ovulation (for example, on day 19 of a regular, 28-day cycle), whichever is later. No additional precaution is required.</li><li>Outside of the above criteria, do not insert the Cu-IUD until pregnancy can be excluded with a pregnancy test performed no sooner than 3 weeks after the last episode of UPSI.</li><li>See the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-ius-iud/index.html">Contraception - IUS/IUD</a> for more information.</li></ul></li><li><strong><strong>If the woman is considering starting t</strong><strong><strong>he</strong></strong> <strong>levonorgestrel intrauterine system (LNG-IUS) </strong>after </strong><strong><strong>ulipristal acetate</strong> EC:</strong><ul><li>Do not insert the LNG-IUS until pregnancy has been excluded with a pregnancy test performed no sooner than 3 weeks after the last episode of UPSI.</li><li>See the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-ius-iud/index.html">Contraception - IUS/IUD</a> for more information.</li></ul></li></ul><!-- end field 01015dc6-18d1-4f83-8733-acbf0138f777 --><!-- end item a0b74429-eed9-4986-aa99-418669479243 --></div></section><section aria-labelledby="after-levonorgestrel" class="ChapterBody-module--wrapper--2HCfk "><h4 id="after-levonorgestrel">How should a woman continue or start ongoing contraception after levonorgestrel emergency contraception?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 4f71bf05-d79a-4fb0-aed5-b7326257e707 --><!-- begin field a3f6855d-ea90-41fc-b534-acbf0138f777 --><ul><li><strong>If the woman is continuing or starting combined hormonal contraception (CHC [pill, patch, and vaginal ring]) after</strong> <strong>levonorgestrel emergency contraception (EC):</strong><br><ul><li>Advise that:<ul><li>She should quick start the contraception, with a pregnancy test 21 days later to exclude pregnancy resulting from EC failure.</li><li>She should use additional contraception (such as a condom) or avoid sexual intercourse until the CHC becomes effective. See the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-combined-hormonal-methods/index.html">Contraception - combined hormonal methods</a> for more information.</li></ul></li></ul></li><li><strong>If the woman is continuing or starting progestogen-only contraception (pill, implant, and injectable) after</strong> <strong>levonorgestrel EC:</strong><br><ul><li>Advise that:<ul><li>She should quick start the contraception, with a pregnancy test 21 days later to exclude pregnancy resulting from EC failure.</li><li>She should use additional contraception (such as a condom) or avoid sexual intercourse until the progestogen-only contraception becomes effective. See the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-progestogen-only-methods/index.html">Contraception - progestogen-only methods</a> for more information.</li></ul></li></ul></li><li><strong>If the woman is considering starting t</strong><strong>he copper intrauterine device (Cu-IUD) </strong><strong>after </strong><strong>levonorgestrel EC:</strong><br><ul><li>Insert the Cu-IUD within the first 5 days (120 hours) after the first episode of UPSI or within 5 days of the earliest expected time of ovulation (for example, on day 19 of a regular, 28-day cycle), whichever is later. No additional precaution is required.</li><li>Outside of the above criteria, do not insert the Cu-IUD until pregnancy can be excluded with a pregnancy test performed no sooner than 3 weeks after the last episode of UPSI.</li><li>See the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-ius-iud/index.html">Contraception - IUS/IUD</a> for more information.</li></ul></li><li><strong><strong>If the woman is considering starting t</strong><strong><strong>he</strong></strong> <strong>levonorgestrel intrauterine system (LNG-IUS) </strong>after </strong><strong>levonorgestrel EC:</strong><ul><li>Do not insert the LNG-IUS until pregnancy has been excluded with a pregnancy test performed no sooner than 3 weeks after the last episode of UPSI.</li><li>See the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-ius-iud/index.html">Contraception - IUS/IUD</a> for more information.</li></ul></li></ul><!-- end field a3f6855d-ea90-41fc-b534-acbf0138f777 --><!-- end item 4f71bf05-d79a-4fb0-aed5-b7326257e707 --></div></section><section aria-labelledby="basis-for-recommendation-be0" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-be0">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item be05922a-bc05-4b05-a12e-44608c133297 --><!-- begin field 620d1ca3-d510-47cb-821c-948439989833 --><p>These recommendations are largely based on the Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <em>Emergency contraception (March 2017, amended December 2020)</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2020</a>] and the Summaries of Product Characteristics (SPCs) for ellaOne<sup>®</sup> (ulipristal acetate) 30 mg tablet [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2017</a>] and Levonelle One Step<sup>®</sup> (levonorgestrel) 1500 microgram tablet [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020</a>].</p><h5>Continuing or starting hormonal contraceptives after ulipristal acetate emergency contraception (EC)</h5><ul><li>Previously, it was recommended that combined hormonal contraception (CHC [pill, patch, and vaginal ring]) and progestogen-only contraception (pill, implant, and injectable) should be quick started immediately after oral EC, with a pregnancy test 21 days later to exclude pregnancy resulting from EC failure. This remains the advice after levonorgestrel EC administration, but not for ulipristal acetate.</li><li>Evidence from a prospective, randomized, pharmacodynamic study (n = 71) identified by the FSRH showed that starting a desogestrel progestogen-only pill (POP) immediately after ulipristal acetate reduces the ability of ulipristal acetate to delay ovulation [<a class="bibliography-reference internal-reference" href="../../references/index.html">Brache, 2015</a>]. There are currently no studies to investigate whether this affects pregnancy rates or whether quick starting other types of hormonal contraception (CHC and the progestogen-only implant and injectable) after ulipristal acetate has the same effect.</li><li>Extrapolating from this evidence, the FSRH recommends that women should wait 5 days (at least 120 hours) after taking ulipristal acetate before continuing or starting a CHC (pill, patch, or vaginal ring) or progestogen-only contraception (pill, implant, or injectable). This ensures that the ulipristal acetate is as effective as possible in preventing pregnancy resulting from the episode(s) of UPSI for which it was taken. Importantly, there is a risk of pregnancy if there is further UPSI before ongoing contraception is started and becomes effective.</li><li>The FSRH points out that there is one specific exception to this: if CHC pills are restarted after a scheduled hormone-free interval and pills are then missed later in the first week of pill taking, ulipristal acetate may be considered, with immediate restart of pill taking. If ulipristal acetate is used in this specific situation, pill-taking can be resumed immediately after taking the ulipristal acetate. See the <a href="https://www.fsrh.org/news/the-fsrh-ceu-statement-regarding-delaying-versus-immediately/" data-hyperlink-id="4530e10e-9746-432b-ae3b-acd3009c5bbd">FSRH CEU statement delaying versus immediate starting COC after UPA-EC use</a> for more information.</li></ul><!-- end field 620d1ca3-d510-47cb-821c-948439989833 --><!-- end item be05922a-bc05-4b05-a12e-44608c133297 --></div></section></section><section aria-labelledby="additional-or-advance-provision-of-emergency-contraception" class="ChapterBody-module--wrapper--2HCfk "><h3 id="additional-or-advance-provision-of-emergency-contraception">Can I give additional or advance supply of oral emergency contraception?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 62cbddd3-746a-403a-82e2-2e3c28e9d8c2 --><!-- begin field f208d4e9-511e-4e6b-abd3-d7207484d044 --><ul><li><strong>Oral emergency contraception (EC) can be used more than once in a cycle. However, manufacturers advise against repeated administration as it can disrupt the menstrual cycle.</strong><ul><li>If a woman has already taken an oral EC once or more in a cycle, the same oral EC can be offered again after further unprotected sexual intercourse (UPSI) in the same cycle. </li><li>If the woman has already taken ulipristal acetate, levonorgestrel should not be taken in the following 5 days.</li><li>If a woman has already taken levonorgestrel, ulipristal acetate could theoretically be less effective if taken in the following 7 days.</li></ul></li><li><strong>Consider prescribing oral EC in advance on an individual basis for women who may be at risk (for example, women relying on barrier methods or travelling abroad).</strong><ul><li>Advise the woman that EC is intended for occasional use and should in no instance replace a regular contraceptive method.</li><li>Explain that:<ul><li>EC does not provide contraceptive cover for the remainder of the cycle and does not provide contraceptive cover for subsequent UPSI.</li><li>There is a significantly increased risk of pregnancy with further UPSI later in the cycle in which oral EC has been taken.</li><li>Repeated administration of EC within a menstrual cycle is not advisable because of the possibility of disturbance of the cycle.</li><li>EC does not protect against sexually transmitted infections (STIs). Only a barrier method of contraception (such as a condom) can reduce the risk of STIs.</li></ul></li></ul></li></ul><!-- end field f208d4e9-511e-4e6b-abd3-d7207484d044 --><!-- end item 62cbddd3-746a-403a-82e2-2e3c28e9d8c2 --></div><section aria-labelledby="basis-for-recommendation-bac" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-bac">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item bac972b4-846c-429e-b6b9-5aab52ca8cc3 --><!-- begin field e05c4855-7c3b-41c5-9cef-732a293e97e9 --><p>These recommendations are largely based on the Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <em>Emergency contraception (March 2017, amended December 2020)</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2020</a>] and the Summaries of Product Characteristics (SPCs) for ellaOne<sup>®</sup> (ulipristal acetate) 30 mg tablet [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2017</a>] and Levonelle One Step<sup>®</sup> (levonorgestrel) 1500 microgram tablet [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020</a>].</p><ul><li>The FSRH found evidence (from systematic reviews) that showed that advance provision of oral emergency contraception (EC) did not reduce pregnancy rates when compared with conventional provision, although EC was taken more frequently and sooner after UPSI if supplied in advance. However, many women in the included trials did not use EC after UPSI despite having a supply. Advance provision did not lead to increased frequency of UPSI, change in contraceptive method use, or increased risk of sexually transmitted infections (STIs).</li><li>The FSRH also identified a randomized trial of advance provision of levonorgestrel EC (plus condoms and an information leaflet) to teenagers in Sweden. The evidence suggested that advance provision shortened the time between UPSI and EC over the following year, without adverse effects on sexual risk-taking or contraceptive use. However, there was a significant loss to follow up in the study.</li></ul><!-- end field e05c4855-7c3b-41c5-9cef-732a293e97e9 --><!-- end item bac972b4-846c-429e-b6b9-5aab52ca8cc3 --></div></section></section></section></div></div></div><div class="BackToTop-module--wrapper--2Z0EU"><nav aria-labelledby="back-to-top-link" class="BackToTop-module--nav--1DPZ6"><a class="BackToTop-module--anchor--1Nia6" id="back-to-top-link" href="index.html#content-start"><div class="container"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="icon" aria-hidden="true" focusable="false"><path d="M478.152 338.576c0 10.091-3.525 18.661-10.576 25.712l-21.424 21.424c-7.243 7.243-15.909 10.864-26 10.864-10.283 0-18.853-3.621-25.712-10.864L255.576 247.136 116.712 385.712c-6.859 7.243-15.429 10.864-25.712 10.864s-18.853-3.621-25.712-10.864l-21.424-21.424C36.621 357.429 33 348.859 33 338.576c0-10.091 3.621-18.757 10.864-26l186-186c7.051-7.051 15.621-10.576 25.712-10.576 9.909 0 18.576 3.525 26 10.576l185.712 186c7.243 7.243 10.864 15.909 10.864 26z" fill="currentColor"></path></svg> Back to top</div></a></nav></div></main><footer class="Footer-module--footer--2QrGZ"><div class="Footer-module--container--1iuoB"><a href="https://www.nice.org.uk/" class="Footer-module--logo--3DGKv" aria-label="Go to NICE home page"></a><nav class="Services-module--wrapper--2qOoE" aria-label="Our services"><ul class="Services-module--list--3SZQu"><li><a href="https://pathways.nice.org.uk/" class="Services-module--link--2y_1q">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Services-module--link--2y_1q">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Services-module--link--2y_1q">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Services-module--link--2y_1q">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary">BNF<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Services-module--link--2y_1q"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Services-module--visuallyHidden--t9mfm">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">Clinical Knowledge Summaries</span></a></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Services-module--link--2y_1q">Journals and databases</a></li></ul></nav><nav class="Pages-module--wrapper--30REl"><ul class="Pages-module--list--vvSk4"><li><a href="https://www.nice.org.uk/about">About NICE</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/into-practice">Into practice</a></li><li><a href="https://www.nice.org.uk/get-involved">Get involved with NICE</a></li><li><a href="https://www.nice.org.uk/get-involved/jobs">Jobs</a></li><li><a href="https://www.nice.org.uk/news">News</a></li><li><a href="https://www.nice.org.uk/news/nice-newsletters-and-alerts">Newsletters and alerts</a></li><li><a href="https://www.nice.org.uk/get-involved/contact-us">Contact us</a></li><li><a href="https://www.nice.org.uk/leave-feedback">Leave feedback</a></li><li><a href="https://www.nice.org.uk/re-using-our-content">Reusing our content</a></li><li><a href="https://www.nice.org.uk/re-using-our-content/uk-open-content-licence">NICE UK Open Content Licence</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/nice-syndication-api">Syndicate our content</a></li></ul></nav><div class="Social-module--wrapper--2nKsd"><ul class="Social-module--list--E5R5J" aria-label="NICE on social media"><li><a href="https://en-gb.facebook.com/NationalInstituteforHealthandCareExcellence/">Facebook</a></li><li><a href="https://twitter.com/NICEcomms">Twitter</a></li><li><a href="https://www.youtube.com/user/NICEmedia">YouTube</a></li><li><a href="https://www.instagram.com/nicecomms/">Instagram</a></li><li><a href="https://www.linkedin.com/company/national-institute-for-health-and-clinical-excellence">LinkedIn</a></li></ul></div></div><div class="Legal-module--wrapper--3AYMO"><div class="Legal-module--container--3TTBh"><nav class="Legal-module--menu--1e1Iy" aria-label="Legal menu"><ul><li><a href="https://www.nice.org.uk/accessibility">Accessibility</a></li><li><a href="https://www.nice.org.uk/freedom-of-information">Freedom of information</a></li><li><a href="https://www.nice.org.uk/glossary">Glossary</a></li><li><a href="https://www.nice.org.uk/terms-and-conditions">Terms and conditions</a></li><li><a href="https://www.nice.org.uk/privacy-notice">Privacy notice</a></li><li><a href="https://www.nice.org.uk/cookies">Cookies</a></li></ul></nav><p class="Legal-module--copyright--34nsI">©<!-- --> <abbr title="National Institute for Health and Care Excellence">NICE</abbr> <!-- -->2021<!-- -->. All rights reserved. Subject to<!-- --> <a href="https://www.nice.org.uk/terms-and-conditions#notice-of-rights">Notice of rights</a>.</p></div></div></footer></div><div id="gatsby-announcer" style="position:absolute;top:0;width:1px;height:1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);white-space:nowrap;border:0" aria-live="assertive" aria-atomic="true"></div></div><script id="gatsby-script-loader">/*<![CDATA[*/window.pagePath="/topics/contraception-emergency/management/management/";/*]]>*/</script><script id="gatsby-chunk-mapping">/*<![CDATA[*/window.___chunkMapping={"polyfill":["/polyfill-2cb897c2a056d28c9332.js"],"app":["/app-53a71c38b210970893c4.js"],"component---cache-caches-gatsby-plugin-offline-app-shell-js":["/component---cache-caches-gatsby-plugin-offline-app-shell-js-258fa972005c75a2a109.js"],"component---src-pages-404-tsx":["/component---src-pages-404-tsx.4b20f8dadfa146d0f95d.css","/component---src-pages-404-tsx-db046304e34e9a4e982b.js"],"component---src-pages-about-development-tsx":["/component---src-pages-about-development-tsx.4c5b5dd941fb0f6fd929.css","/component---src-pages-about-development-tsx-a805dcaba6372bd3fd34.js"],"component---src-pages-about-index-tsx":["/component---src-pages-about-index-tsx.a9a4b7f951b698486005.css","/component---src-pages-about-index-tsx-d5e998d3f688352286e1.js"],"component---src-pages-index-tsx":["/component---src-pages-index-tsx.49dafffcf9ae0c5f0d9f.css","/component---src-pages-index-tsx-6cc2ff789de11ec327f6.js"],"component---src-pages-search-tsx":["/component---src-pages-search-tsx.f915457cd8b05c27e895.css","/component---src-pages-search-tsx-a51f99760cb0d47808e2.js"],"component---src-pages-specialities-tsx":["/component---src-pages-specialities-tsx.fc62cf637c7ba1e609e7.css","/component---src-pages-specialities-tsx-90b8d3e5a5a3bff52a17.js"],"component---src-pages-topics-tsx":["/component---src-pages-topics-tsx.dfa0c1027e3cbeb11bdc.css","/component---src-pages-topics-tsx-960f75c13acbee11c017.js"],"component---src-pages-whats-new-tsx":["/component---src-pages-whats-new-tsx.7f7660f22ce5e07ac85a.css","/component---src-pages-whats-new-tsx-f78b713a66b42005fd9f.js"],"component---src-templates-chapter-level-1-chapter-level-1-tsx":["/component---src-templates-chapter-level-1-chapter-level-1-tsx.1a16ce552cccd7e50c41.css","/component---src-templates-chapter-level-1-chapter-level-1-tsx-0a03778bb80ba711929e.js"],"component---src-templates-chapter-level-2-chapter-level-2-tsx":["/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css","/component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"],"component---src-templates-speciality-speciality-tsx":["/component---src-templates-speciality-speciality-tsx.fc62cf637c7ba1e609e7.css","/component---src-templates-speciality-speciality-tsx-3357943d471e489a1b5f.js"],"component---src-templates-topic-topic-tsx":["/component---src-templates-topic-topic-tsx.afc04214919e241c3c2e.css","/component---src-templates-topic-topic-tsx-f17fe03d0b9a54a96aea.js"]};/*]]>*/</script><script src="../../../../polyfill-2cb897c2a056d28c9332.js" nomodule=""></script><script src="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js" async=""></script><script src="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js" async=""></script><script src="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js" async=""></script><script src="../../../../app-53a71c38b210970893c4.js" async=""></script><script src="../../../../framework-34da02e39e1f104d9937.js" async=""></script><script src="../../../../webpack-runtime-28c424ef71f39faedaf0.js" async=""></script></body></html>